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 Abstract 
Overexpression of HER-2/neu in breast cancer is strongly correlated with more 
aggressive phenotypes and adverse clinical outcomes. Understanding the mechanism(s) of 
action of this receptor in breast tumor progression is imperative. In this study, proteomics 
had been employed to analyze the HER-2/neu-linked protein profiles in breast tumor 
microenvironment. The proteome profiles of the HER-2/neu-positive and -negative breast 
tumors were generated with two-dimensional gel electrophoresis. Combinations of 
different pH ranges of IPG dry-strips were used to achieve high resolution separation of 
the proteins and the proteome profiles were matched and compared for the differentially 
expressed proteins. With the aid of MALDI-TOF/TOF MS/MS and bioinformatics tools, 
38 proteins were identified. Functional analysis using Gene Ontology, revealed that these 
proteins were mainly involved in intermediary metabolism, structural organization, 
molecular transportation, protein folding and assembly, anti-oxidative and cellular 
detoxification, RNA processing and signaling pathway inhibitions. Relative expression 
based on signal intensities from Western blots using more clinical specimens displayed a 
similar trend of expression as those observed on 2DE images, confirming our proteomics 
results. In addition, immunohistochemistry on tissue microarray had provided statistically 
significant differential expression of the proteins. Multiple spots detected using specific 
monoclonal antibodies in 2D immunoblotting had also demonstrated differential 
regulation of post-translational modifications by the HER-2/neu. With all these results, 
we firmly established the differential regulation of protein expression and post-
translational modifications by HER-2/neu in breast cancer. 
These are additional data that contribute towards a better understanding of the possible 
mechanism of actions of HER-2/neu-mediated breast cancer. 
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  Abbreviation 
NO. Name Abbreviation 
1 Aldo-keto reductase AKR 
2 Atypical Hyperplasia ADH 
3 Breast Cancer Associated Gene 1 and 2 BRCA1 and 2 
4 Cytokeratin-19 CK19 
5 Differential gel electrophoresis DIGE 
6 Ductal carcinoma in-situ DCIS 
7 Electrospray Ionization ESI 
8 Enolase 1 ENO1 
9 Enzyme-linked immunosorbent assay ELISA 
10 Epidermal growth factor EGF 
11 Estrogen receptor  ER 
12 Fattyacid synthase FASN 
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14 Fibroblast Growth Factor-2 FGF-2 
15 FGF receptor substrate FGFRS 
16 Fluorescence in-situ hybridization   FISH 
17 Food and Drug Administration FDA 
18 Hyperplasia of Usual Type HUT 
19 Gloxalase I GLO1 
20 Glucose Related Protein 78  GRP78 
21 Glutathione transferase GST 
22 Glyoxylate reductase/hydropyruvate reductase  GPHPR 
23 Heat shock protein 27 Hsp27 
24 Heregulin HRG 
25 High-pressure liquid chromatography HPLC 
26 Human Genome Project HGP 
27 Immunohistochemistry IHC 
28 Isoelectrical point pI 
29 Isotope coded affinity tagging ICAT 
30 Laser Captured Microdissection LCM 
31 Lobular carcinoma in-situ LCIS 
32 Manganesse Superoxide Dismutase MnSOD 
33 Mass spectrometry MS 
34 Matrix-Assisted Laser Desorption Ionization-Time-of Flight MALDI-ToF 
35 Mitogen-activated protein kinase MAPK 
36 Multidimensional protein identification technology    MudPIT 
37 neu differentiation factor NDF 
38 Peptide mass fingerprinting PMF 
39 Phosphoglycerate kinase 1 PGK1 
40 Phospholipase C- γ PLC-γ 
41 Phosphotidylinositol 3-Kianse PI3K 
42 Platelet-derived growth factor PDGF 
43 Progesterone receptors   PR 
  
 
44 Prolyl-4-hydroxylase  P4HB 
45 Protein kinase C PKC 
46 Raf-1 kinase inhibitor protein RKIP 
47 Receptor tyrosine kinases RTKs 
48 Reverse phase RP 
49 Sodium dodecylsulphate SDS 
50 Strong cation exchange SCX 
51 Surface enhanced laser desorption and ionization SELDI 
52 Tissue Microarray TMA 
53 Tris-buffered saline containing 0.1% Tween-20 TBS-T 
54 Triose-phosphate isomerase TPI 
55 Two-Dimensional Gel Electrophoresis 2DE 
56 Voltage dependent anion channel protein VDAC 
 1. Introduction 
1.1. Breast Cancer 
1.1.1 Incidence of Breast Cancer  
Breast cancer is the leading cause of cancer death among women globally. The incidence 
of breast cancer was 1,151,298 in 2002, of which 410,712 death cases were reported [1]. 
Breast cancer has been the primary cause of death for women in Singapore since 1998 
[2]. Records from Singapore Cancer Registry showed that annual average breast cancer 
cases in Singapore from 1998 to 2002 was 1741. Within the same period of years, the 
mortality rate was 15.7% comprising of 273 deaths annually. In addition, a study done by 
the Johns Hopkins Singapore Clinical Services has established that the incidence of breast 
cancer in premenopausal women is higher (5.9% per year) as compared to 
postmenopausal women (3.9% per year) [2]. In the periods of  1968-1972 and 1988-1992, 
Malays in Singapore have the highest (4.4%) and Indians have the lowest (1.4%) average 
annual increase rate [3]. Overall, breast cancer incidence rate are likely to increase more 
sharply in the future as women born after the mid-20th century, during the post World 
War ‘baby boom’ reach the high-risk age groups [3]. Hence there is a need in finding 
precise therapeutic measures for proper management of breast cancer. 
 
1.1.2. The Progression of Breast Cancer 
Breast cancer is a heterogeneous disease encompassing a group of several important 
tumor subtypes, each with a different natural history, manifesting a wide range of 
pathological entities and clinical behavior and each requiring a different treatment [4]. 
The primary lesion of neoplastic breast disease could arise from either the ducts or the 
lobular region of the breast (Figure 1). The precursor for ductal breast carcinoma is what 
is termed ‘hyperplasia of usual type’ (HUT) which will then develop into atypical ductal 
hyperplasia (ADH), whereas, the initial stage of lobular breast carcinoma is defined only 
 by atypical lobular hyperplasia (ALH). There could then be progression of the atypical 
hyperplasia into ductal or lobular carcinoma in situ (DCIS or LCIS), which is 
characterized by limited proliferation of malignant epithelial cells within the breast 
parenchymal structures, with no evidence of invasion across the basement membrane [5] 
(Figure 3). If undetected or untreated, DCIS or LCIS could progress to ductal or lobular 
invasive carcinoma (IDC or ILC) due to the infiltration of the malignant precursor across 
the basement membrane into the stroma [6] (Figure 3). This ultimately leads to metastasis 












Figure 1: The anatomy of the breast. The breast is mainly made up of A: Duct; B: Lobule; C: Dilated 
duct for milk holding and D: Fatty tissues. Within the duct (Inset), it consists of I: Normal duct 
epithelial cells; II: Basement membrane; and III: Lumen. The initial precursor of the malignancy could 
arise in the duct (A) or lobules (B).  















Normal ADH DCIS IDC HUT 
ALH LCIS ILC 
Figure 2: The multistep development of breast carcinoma. Breast cancer has been sub-classified 
into ductal or lobular carcinoma. There are three main stages in the development of breast cancer: 
atypical hyperplasia, in situ carcinoma, and invasive carcinoma. 
Normal DCIS IDC 
Figure 3: Breast tissue morphology.  (I). Normal breast with normal epithelial cells and intact 
basement membrane.  (II). DCIS breast with malignant transformation of epithelial cells into tumor 
cells but confined to the duct with no penetration of cells across basement membrane. (III)  IDC breast 
with abnormal proliferation of the epithelial cells infiltrating into the damaged basement membrane 
and penetrating into the stroma. 
Pictures were modified from www.breastcancer.org. 
 
 
 1.1.3. The Etiology of Breast Cancer 
The etiology of breast cancer is not well-known [7]. Age is probably the most important 
risk factors as breast cancer, as with most other cancers, develops as a result of 
cumulative effects of multiple mutations after many years. Singapore Cancer Registry has 
revealed that the peak incidence for Singaporean women occurs between 50 and 55 years, 
from the cases reported from 1998 to 2002. Other susceptible factors have been reported 
including parity, age at the first pregnancy, breastfeeding, age at menarche and age at 
menopause, estrogen treatment after menopause, environment, stress, and nutrition [8].  
A familial history of breast cancer is another major predisposing risk factor, emphasizing 
the role of genetics in this pathology. About 10% of all breast cancers are associated with 
an inherited genetic abnormality. Mutations in the Breast Cancer Associated Gene 1 and 2 
(BRCA1 and 2) are the most frequent genetic abnormality. Women with BRCA1 
mutations are more likely to be estrogen receptor negative [9]. This renders treatment by 
Tamoxifen, an anti-estrogen which is a therapeutic intervention currently widely used 
much less effective.  HER-2/neu which encodes for the epidermal growth factor receptor 
type-2 expressed on the surface of breast cells is another commonly affected gene in 
breast cancer. Amplification of the HER-2/neu gene or overexpression of the HER-2/neu 
encoded receptor occurs in 20-30% of breast cancer  [10, 11] and causes more aggressive 
form of breast cancer. 
 
 1.2 HER-2/neu (Erb B2) 
1.2.1 The Structure and Functions of HER-2/neu 
 
HER-2/neu or ErbB 2 oncogene was originally isolated from rat neuroblastoma. The 
human HER-2/neu gene counterpart was subsequently identified from human cDNA 
libraries [12, 13]. It is located on chromosome 17 and encodes a 185-kDa transmembrane 
glycoprotein. The HER-2/neu encoded protein, also known as c-erbB2 contains a 95-110 
kDa cysteine-rich extracellular ligand binding ectodomain, a hydrophobic membrane-
spanning domain (3 kDa) and a short juxtamembrane segment, and an intracellular 
tyrosine kinase domain (70-90 kDa) linked to a carboxyl (C)-terminal tail [14] (Figure 4). 
A truncated form of the HER-2/neu receptor, comprising only the soluble ectodomain has 
been found in a variety of tumor cell lines and tumor tissue samples. It is believed that the 
presence of the truncated form is due to proteolytic cleavage at two polymorphic sites of 
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Figure 4:  The topology of the HER-2/neu receptor. It consists of an extracellular ligand- binding 
domain (ECD), a single transmembrane domain (TMD), a juxtamembrane segment (JMS), and an 
intracellular tyrosine kinase domain (TKD) as well as C-terminal tail. The polymorphic sites in the 
TMD might favor the generation of a truncated form comprising of only the N-terminal ectodomain. 
 HER-2/neu is a member of the epidermal growth factor receptor (EGFR) or the class I 
family of receptor tyrosine kinases (RTKs). Other family members include HER-1 (erbB-
1), HER-3 (erbB-3) and HER-4 (erbB-4) which share significant sequence homology [15] 
as well as functional similarity. However, heteromerization with other members within 
the family may be an obligate event for its activation, as there is as yet no known ligand 
identified with the HER-2/neu receptor.  
Its crystal structure has revealed a constitutive open structure of HER-2/neu [16] which 
appears to allow it to release an auto-inhibited conformation independent of ligand and to 
interact with other binding partners in the absence of direct ligand binding [16]. It is 
believed that heterodimerization confers a more stable complex and potent signaling [17] 
by increasing the ligand affinity through decelerated rate of ligand dissociation and a 
decrease rate of receptor downregulation.  
 In most recent studies on HER-2/neu-associated pathways and functional networks, 
stimulation with Heregulin (HRG) or neu differentiation factor (NDF) is used as a 
triggering mechanism. HRG, a 45kDa protein exists in multiple secreted isoforms derived 
from alternatively spliced genes [18]. These studies revealed that HRG binds specifically 
to HER-3 or HER-4 with relative low activity but is not capable of binding to HER-2/neu 
on its own [15]. In addition, NIH 3T3 cells expressing only either HER-2 or HER-3 
showed no tyrosine phosphorylation in response to HRG but demonstrated 
phosphorylation when both receptors were expressed together in the cells [15]. Thus, only 
the heterodimerization of HER-2/neu with either HER-3 or HER-4 could form stable 
complex with receptor response towards HRG leading to activation of HER-2/neu 
receptor [15].  
Upon activation after heteromerization with HER-3 or HER-4, the juxtamembrane 
segment of the HER-2/neu could be phosphorylated by protein kinase C (PKC) whereas 
the C-terminal tail containing tyrosine groups appears to be the phosphorylation site for 
 the tyrosine kinases [15]. The phosphorylated residues are then the likely docking sites 
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Figure 5:  The functional domains of HER-2/neu. The extracellular region (ECD) allows the binding 
of ligands as well as interaction with other receptors. The juxtamembrane (JMS) and C-terminal tail are 
the phosphorylation sites for PKC and tyrosine kinases respectively. The tyrosine kinase domain 
(TKD) might function to autophosphorylate the C-terminal on the same receptor or transphosphorylate 
the partner receptors.  [TMD: Transmembrane domain] 
 1.2.2. Intracellular Signaling Networks 
There are multiple signaling networks that could be stimulated upon HER-2/neu 
activation (Figure 6). The primary signaling pathway triggered by the activated HER-
2/neu  is the mitogen-activated protein kinase (MAPK) pathway [19] which ultimately 
targets many transcription factors. The evidence for the activation of the MAPK pathway 
by HER-2/neu signal transduction was provided by the ability of T47D human breast 
cancer cells, which expressed all four members of the class I RTK family, to induce the 
MAPK activation after treatment with HRG. However, the MAPK activation was 
decreased when HER-2/neu expression was reduced through antibody-mediated 
intracellular retention of the HER-2/neu in the endoplasmic reticulum (ER) [20].  
Phosphotidylinositol 3-Kinase (PI3K)/Akt signaling is needed for cell survival and cell 
growth. It is another important signaling pathway that could be stimulated with HER-
2/neu activation. The activation of PI3K/Akt by HER-2/neu had been previously 
demonstrated by the phosphorylation of the p85 subunit (regulatory subunit) of the PI3K 
after ligand-induced stimulation of the HER-2/neu in human breast cancer cells. p85 had 
also been shown to be co-immunoprecipitated with the activated HER-2/neu [21].  
The phospholipase C- γ (PLC)-associated pathway, which is involved in mobilization of 
intracellular calcium and possible activation of raf-1 via protein kinase C (PKC) [15] had 
also been shown to be one of the HER-2/neu-related signaling pathways. Association and 
activation of PLC γ had been observed in cells overexpressing the human HER-2/neu and 
the oncogenic rat neu-encoded receptors [15]. Unlike the MAPK and PI3K pathways, the 




























Figure 6: HER-2/neu activated signaling pathways. HER-2/neu could form heterodimers with other 
members of the RTKs to trigger multiple downstream signaling pathways, which promote cell 
proliferation and differentiation. 
 
 1.2.3. Clinical Significance of HER-2/neu in Breast Carcinoma 
Overexpression or uncontrolled expression of the HER-2/neu protein is an aberrant 
phenomenon frequently seen in many cancers, especially breast carcinoma. The 
amplification of the HER-2/neu gene appears to be the most common mechanism leading 
to disturbance of HER-2/neu protein expression [22]. Amplification of the HER-2/neu 
gene has resulted in overexpression of the HER-2/neu receptor in 90% of the cases. 
However, in 10% to 12% of the cases, the HER-2/neu protein overexpression may result 
from transcriptional or post-transcriptional dysregulation [22, 23] without gene 
amplification. The structure of the overexpressed HER-2/neu protein had been shown to 
be the same as that found in normal epithelial cells [22].  
HER-2/neu is considered to be overexpressed in tumors when levels are higher than the 
very low levels found in normal tissues. In normal breast epithelial cells, there are 2 
copies of the HER-2/neu gene and between 20,000 and 50,000 HER-2/neu receptors [24] 
will be expressed on the cell surface. In contrast, tumor cells that overexpressed HER-
2/neu protein, either through gene deregulation or amplification, may have enhanced 
expression of about 10- to 100-fold [4] where about 2 million receptors [24] could be 
detected. 
 
1.2.4. The Findings on HER-2/neu-Mediated Breast Carcinoma 
The adverse clinical outcomes observed in the breast cancer patients overexpressing 
HER-2/neu have led to intensive study of this receptor. Many had reported that increased 
expression levels of HER-2/neu in cancer cells indeed provided a growth advantage [25, 
26]. This had been verified in a NIH 3T3 model where overexpression of HER-2/neu had 
resulted in malignant transformation [27, 28]. Moreover, overexpression of HER-2/neu in 
the mammary glands of transgenic mice had also been demonstrated to induce focal 
breast cancer as well as metastasis [27].  
 However, understanding the precise mechanisms by which HER-2/neu are involved in 
breast cancer progression has remained a challenge. It stands to reason that signal 
transduction pathways that are stimulated upon HER-2/neu activation are likely to play 
important roles. In the normal epithelial cell, copy numbers of the HER-2/neu receptor 
and its interacting partners would be stringently controlled to provide optimal, transient 
level of signal for regulated cell growth and survival.  In the case of HER-2/neu 
overexpression, there could be spontaneous receptor heteromerization, constitutive 
receptor activation [29] and excessive signaling pathways stimulation, leading to 
disruption of normal cellular control and malignant transformation of cells in a ligand-
independent manner [30].  
Heteromerization has since been tested as an obligatory pre-requisite for the HER-2/neu-
mediated breast tumorigenesis. It had been demonstrated that initiation of HER-2/neu 
oncogenic signaling was dependent on HER-2/HER-3 heteromerization after HRG 
stimulation [31]. The physiological relevance of this heteromerization had been 
confirmed with the HRG- induced transformation of NIH 3T3 cells co-expressing the two 
receptors [31]. The involvement of HER-2/HER-3 heteromerization in breast cancer had 
also been further supported in another study by Halbro et.al.  In this study, down-
regulation of HER-3 in the HER-2/neu overexpressing cell line, SkBR3, had shown G1 
arrest and retarded proliferation [32]. All these findings had suggested HER-2/HER-3 
heteromerization is essential to drive the proliferation of breast cancer.  
In the same studies by Halbro et.al., it had been shown that PI3K pathway could be 
stimulated after HER-2/HER-3 heteromerization [32]. The involvement of PI3K pathway 
in HER-2/neu-mediated breast cancer had then been further recognized when MCF-7 
breast cancer cells exhibited enhanced cell aggregation with PI3K pathway activation 
[18]. Furthermore, a study had shown that HER-2/neu overexpressing human mammary 
cells displayed an increased requirement for PI3K signal pathway to promote anchorage-
 independent growth [33]. This associated the up-regulation of HER-2/neu receptor to the 
PI3K signaling stimulation and malignant phenotypes of the cells. 
In a study of gene expression profiling of HER-2/neu-induced tumors from transgenic 
mice, the expression of several known transforming growth factor (TGF)-β target genes 
was reduced, mooting the proposal that the TGF-β pathway may be one of the signaling 
networks that are regulated by HER-2/neu during tumorigenesis. 
The Extracellular Regulating Kinase (ERK) signaling pathway had also been observed to 
be associated with HER-2/neu overexpression. This had been revealed in a study 
involving NIH 3T3 cells overexpressing HER-2/neu where ERK pathway stimulation was 
shown to be necessary to repress the expression of a metastasis suppressor, RECK in 
order to promote cell invasion [34]. 
A number of potential targeted genes or proteins involved in HER-2/neu-mediated 
signaling pathways had also been evaluated. The expression of these targeted genes/ 
proteins had been shown to be regulated by the HER-2/neu-mediated signaling pathways 
and these genes / proteins were observed to be necessary to promote the tumorigenesis.  
For example, the fatty acid synthase (FASN) enzyme was found to be up-regulated in a 
transcriptome analysis of a panel of HER-2/neu overexpressing breast cancer cell lines 
[35]. It was shown to be activated through the PI3K pathway suggesting FASN to be one 
of the HER-2/neu regulated genes through the activated signaling pathways. FASN might 
promote tumorigenesis through its role in cell proliferation and membrane lipid 
incorporation of neoplastic cells [35]. 
The studies on the targeted genes or proteins have anticipated HER-2/neu to play a direct 
causal role in invasion and metastasis. Vascular endothelial growth factor (VEGF), which 
is essential for the angiogenesis, was found to be regulated by the HER-2/neu-mediated 
PI3K pathway [36]. In another study, matrix metalloproteinase-9 (MMP-9) was shown to 
 be up-regulated by protein kinase C (PKC) and p38 kinase in a HRG-treated breast cancer 
cell line [37], suggesting a role for proteolytic enzyme in invasion and metastasis.   
A plausible functional link between the HER-2/neu and chemokine receptors may yet 
represented an additional signaling pathway. Chemokines are a superfamily of small, 
cytokine-like peptides. Interaction with their specific receptor, G-protein-coupled seven 
transmembrane receptor (GPCR), could induce cytoskeleton rearrangement of 
hemotopoietic cells, increase their adhesion, and direct them to migrate to home-specific 
organ. Thus, chemokines and their receptors may have an important role in targeted 
metastasis of cancer. A significant correlation between HER-2/neu and CXCR4 (a 
chemokine receptor) expression was observed in human breast cancer tumor tissues [38], 
a finding that has offered an alternative mechanism for HER-2/neu-regulated breast tumor 
metastasis. 
All these findings have added valuable indications to the HER-2/neu mediated breast 
cancer progression. However, the precise molecular links of these molecules to the HER-
2/neu overexpression remains unclear and active assessments are still needed. 
 
 1.2.5. The Evaluation of HER-2/neu Overexpression 
There are many techniques available for the analysis of HER-2/neu expression. These 
include immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA) and 
Western blotting for the HER-2/neu protein detection using a specific antibody. On the 
other hand, fluorescence in-situ hybridization (FISH,) Southern and slot blotting have 
been employed for evaluating the gene expression status of HER-2/neu. Experts are still 
debating on the best method for the assessment HER-2/neu expression due to certain 
inherent technical inconsistencies of each technique. Currently, IHC and FISH (Figure 7) 
are the most widely available evaluation methods. There are commercially available U.S 
Food and Drug Administration (FDA)-approved assays for the HER-2/neu determination 
with IHC (HercepTest IHC assay; Dako) and FISH (PathVysion; Vysis, Drowners Grove, 
IL; and INFORM, Ventana Medical System, Tucson, AZ). Recent studies had 
demonstrated that these two techniques share a high degree of concordance in 90% of the 
samples tested when the HER-2/neu status was determined to be negative or strongly 
positive by IHC analysis [39-41]. However, discordant results might be obtained with the 
moderately positive IHC results. These discrepancies are most likely due to the lack of 
the standardization of scoring systems rather than the pre-analytical issues such as tissue 
fixation or the tumor heterogeneity [42]. Since IHC is widely available, and can be 
performed at relatively low cost and is less complicated than FISH,  it has been 
recommended for use as a screening step followed by FISH in borderline cases with 











1.2.6. The Occurrence of HER-2/neu Overexpression in Breast Carcinomas 
HER-2/neu is frequently amplified or overexpressed in breast cancers. This gene 
amplification and receptor overexpression are associated with about 30% of breast 
cancers suggesting a critical role for HER-2/neu overexpression in the development of 
breast carcinoma [24]. The HER-2/neu overexpression had been observed in 65% of 
preinvasive DCIS (HUT), 65% of DCIS, 30% of IDC and 50% of inflammatory breast 
cancer cases [44] (Figure 8B).  Overexpression of HER-2/neu is also found in other types 
of cancer with relatively high incidence [24] (Figure 8A) but the extent of  HER-2/neu  
expressed is much less compared to breast cancer and without evidence for gene 
amplification being detected. Furthermore, the role of HER-2/neu in these cancers is less 
well studied. 
 
Figure 7: The assessment of HER-2/neu with IHC and FISH. The HER-2/neu gene and protein 
expression levels could be evaluated with FISH and IHC respectively. In the HER-2/neu-positive 
sample, there was very strong red staining of cell membrane when tested with IHC and fluorescent 
detection in nucleus was observed with FISH. 
(Adopted with permission from Zhang et. al: Evaluation of HER-2/neu oncogene status in breast 





























































































































Figure 8: Incidence of HER-2/neu overexpression. (A). Bar chart showing the median frequency of 
HER-2/neu overexpression in various cancers. (B). The incidence of HER-2/neu overexpression in 
different breast cancer stages.  
Data obtained from Lohrish C and Piccart M: An Overview of HER2. Seminars in Oncology 2001, 
28:3-11 and Menard S et. al.: HER-2 overexpression in various tumor types, focusing on its 
relationship to the development of invasive breast cancer. Ann Oncology 2001, 12: S15-S19 
 1.2.7. The Association of HER-2/neu with Clinicopathological Parameters 
Overexpression of HER-2/neu oncogene in human breast carcinoma is associated with 
adverse outcome and poor prognosis as it promotes a more aggressive course of disease 
[45]. The overall survival (OS) rate of cancer patients with tumors overexpressing HER-
2/neu is significantly shorter and this population of patients had been reported to have 
comparatively worse relapse-free survival (RFS) rates in many studies [46].  Increased 
HER-2/neu overexpression had also been demonstrated to correlate with many other 
clinicopathological parameters. The HER-2/neu positivity is strongly and inversely 
related to estrogen receptor (ER) and progesterone receptor (PR) where the incidence of 
HER-2/neu enhancement is doubled in either ER- or PR-negative patients [46].  In 
addition, most of the studies suggested that overexpression of HER-2/neu had resulted in 
more serious malignant growth characteristics. The DNA synthesis rate is higher with 
high frequency of tumors expressing aneuploidy [46]. Increased cellular proliferation had 
also been shown to be positively associated with the overexpression in HER-2/neu-
positive cancer with bigger tumor size, lymph node infiltration and/or high grade tumors 
[45]. Certain oncogenes and tumor suppressors had also been linked to HER-2/neu 
overexpression. These genes include  p53, c-myc and p21 ras as well as topoisomerase II 
[45]. Furthermore, HER-2/neu also appeared to induce resistance to a panel of 
chemotherapeutic agents such as paclitaxel under certain experimental conditions [19]. It 
is believed that the resistance developed is due to enhanced expression of p21, which 
inhibits cyclin B/cdc2 kinase activity in G2/M phase, which is required for paclitaxel-
induced apoptosis [19]. 
 1.2.8. Therapeutic Interventions on HER-2/neu Overexpression 
Choosing the most optimal therapeutic approach for the HER-2/neu overexpressing 
patients has been vexing. Several lines of evidence have suggested the patients with this 
subtype of tumor have reduced response to conventional treatment such as tamoxifen. 
Thus, alternative therapeutic agents are needed for the treatment of this subgroup of the 
patients. 
The realization and awareness of the multiple adverse proliferative signals induced by 
HER-2/neu in breast cancer have led to targeting of the HER-2/neu networks in breast 
cancer treatment. HerceptinTM (trastuzumad; Genetech; South San Francisco, CA) is the 
most recommended HER-2/neu targeted therapeutic agent for HER-2/neu overexpressing 
tumors [47]. It is a humanized MAb directed to residues 529-626 in the HER-2/neu 
ectodomain and was engineered by inserting the complementary determining region of a 
murine antibody (Clone 4D5) into the framework of a consensus human IgG [47, 48].  
Several molecular and cellular effects of the Herceptin have been extensively described 
although the precise mechanism of action of Herceptin remains to be elucidated. It has 
been demonstrated that Herceptin is able to suppress the highly inducible signaling 
pathways such as PI3K and MAPK [48] through the Herceptin-mediated internalization 
and degradation of HER-2/neu [47]. Besides, Herceptin-treated cells have been shown to 
undergo cell cycle arrest at the G1 phase with concomitant reduction of cell proliferation 
and expression of a sequester protein, cyclin-dependent kinase (cdk) inhibitor p27kip1 [47]. 
A study had also shown that Herceptin blocks the metalloprotease-induced cleavage of 
HER-2/neu in generating a 95kDa amino-terminal membrane associated fragment and 
shedding of the ectodomain which is associated with poor clinical outcome [48]. 
Therefore Herceptin is effective for HER-2/neu-overexpressing patients. 
Though Herceptin treatment is promising, many other new potential candidates targeting 
HER-2/neu are still under active evaluations. The antisense oligonucleotides have been 
 proposed to repress the expression of HER-2/neu and this had been demonstrated with the 
breast cancer cell lines overexpressing HER-2/neu [46]. Repression of HER-2/neu 
expression by targeting the promoter has been suggested using 12S and 13S Ad5 E1A 
protein. Transfection of E1A into an HER-2/neu-transformed mouse fibroblast cell line 
virtually abolished the tumorigenesity and metastatic potential induced by the HER-2/neu 
[49]. The phase I clinical trial of DC-Chol-mediated E1A gene therapy for breast cancer 
patients overexpressing HER-2/neu was performed and has been recently completed. The 
outcome of the patients treated with this agent was encouraging and phase II study will be 
initiated shortly [49]. 
 
 1.3. Proteomics 
1.3.1. An Overview of Proteomics 
In the past century, genomics has undergone revolutionary changes with the emergence of 
a variety of molecular biology techniques [50] that have been customized for  decoding 
the genetic information of human and other species. Our knowledge on the genome level 
has increased massively with the advancement made possible by the Human Genome 
Project (HGP) to sequence more than 30,000 human genes. With the completion of HGP 
few years ago, the structural and functional genomics or post-genomic era has been 
initiated to use the gene sequences to predict the resultant proteins and to study their 
structures as well as functions. However, the level of mRNA expression frequently does 
not accurately reflect the amount and nature of the proteins in a cell [51]; the gene 
sequence does not provide information on the post-translational modifications which may 
be essential for the protein function and activity [51]. Furthermore, the dynamic cellular 
process cannot be fully described by the genome itself [51]. Proteomics which allows the 
global analysis of the cellular proteins has thus been introduced to resolve the information 
that is not obtainable from the genomic studies. 
Proteomics is an area of research that uses a combination of sophisticated systems 
including protein separation techniques such as two-dimensional gel electrophoresis, 
image analysis, and mass spectrometry, amino acid sequencing and bioinformatics to 
resolve comprehensively, to quantify, and to characterize proteins [51]. There are many 
available proteomics technologies that have been well developed and explored to assist in 
acquiring the required knowledge. 
 
 1.3.2. Proteomics Techniques 
1.3.2.1. Gel-Based Proteomics Approach 
1.3.2.1.1. Two-Dimensional Gel Electrophoresis (2DE)  
2DE is a gel-based proteomics approach where the proteins are separated on the basis of 
charge in the first dimension and molecular mass in the second dimension. On the 
application of a current, the solubilized, denatured and charged polypeptides undergo 
isoelectrical focusing by migrating in a polyacrylamide gel strip that contains an 
immobilized pH gradient until they reach the pH at which their overall charge is neutral 
i.e. their respective isoelectrical points or pIs. This produces a gel strip containing discrete 
protein bands along its length. This gel strip is then applied to the edge of a rectangular 
slab polyacrylamide gel containing sodium dodecylsulphate (SDS-PAGE) at 90° to the 
first gel direction, and the focused polypeptides allowed to migrate in an electric current 
into the second gel and are separated on the basis of their molecular sizes [50]. 
Visualization of the proteins following 2DE could be carried out in many ways with 
different sensitivity levels. Silver staining is the most popular staining application due to 
its ability to detect proteins in the 2-5ng range as compared to Coomassie brilliant blue 
stain, which can detect proteins only at greater than 100ng [51]. Recent advances in 
proteomics has allowed development of new fluorescent dyes such as the SYPRO series 
of protein dyes which are aimed at further improving the sensitivity of protein detection 
[51].  
One of the limitations of 2DE is that it is very time-consuming especially with the large-
format gel where at least 24hr is needed to complete the whole process. This technique 
also cannot provide absolute quantitation on protein expression due to the limited 
dynamic range of the staining techniques [52]. As a result, the intensity of the relatively 
more abundant spots is not linearly correlated to that of the less abundant spots. 
Furthermore, post-translationally modified proteins such as phosphorylated proteins can 
 give quantitatively and qualitatively different staining intensities when compared to 
similar amounts of other non-modified proteins. Due to the limited sensitivities of the 
available staining methods, the low abundant proteins are usually not detected and have 
been ‘masked’ or underestimated during the analysis [52, 53]. The reproducibility is also 
always a moot point and robust results can only be obtained after extensive replications 
have been performed and with replication falling within acceptable limits of analytical 
reliability [52, 54]. The most important drawback of this technique is that it does not 
work well with “hydrophobic” proteins particularly those with high molecular weights 
due to the problem of the selective insolubility. However, this drawback has been 
somewhat mitigated in recent years by the introduction of detergents with improved 
formulation and greater solubility power [53].  
Despite the disadvantages, 2DE remains the method of choice of many proteomics 
research as it can be used to visualize a large number of proteins simultaneously. This is 
particularly important when a study is aiming to unravel the many complex relationships 
between proteins in functioning cells or to collect as many of the expressed proteins as 
possible to build up a database of expressed proteins [53].  
Furthermore, 2DE allows relative quantitation of a specific protein under the differential 
condition being studied as the presence or absence of one or more spots in one gel when 
compared to another is readily detectable. With the application of appropriately designed 
computer software to correct for “background” and other operational factors, sufficiently 
accurate normalized intensities of a pair of matched spots on the gels can be obtained to 
reflect the differential expression of the protein of interest. Using this technique, the state 
of a cellular system in response to an overexpressed signaling protein or a particular 
treatment can be assessed by comparing the expressed proteomes from each state. 
Thus, despite numerous drawbacks, 2DE remains a useful and indispensable tool in 
proteomics, if performed correctly.  
 1.3.2.1.2. Differential Gel Electrophoresis (DIGE) 
Differential gel electrophoresis (DIGE) is an improved form of 2DE-based proteomics. 
This technique involves the covalent labeling of proteins with  mass- and charge- 
matched N-hydroxyl succinimidyl ester derivatives of fluorescent dyes [55] such as 
cynanine (Cy2, Cy3 or Cy5) [56] at lysine residues, without affecting the solubility and 
the migration of the protein during the separation step [57]. Briefly, the “test” protein 
sample is labeled with Cy3 and the reference sample with Cy5. Equal concentrations of 
the differentially labeled protein samples are mixed and co-separated through the same 
2DE process as explained in section 1.3.2.1.1. The gel image is then visualized by 
scanning the gel at two wavelengths using a fluorescence imager as the dyes possess 
distinct excitation and emission spectra. A comparison of the images generated by 
scanning of the gel at the Cy3 and Cy5 wavelengths allows the quantitation of each spot 
with the accompanying image analysis software. This method effectively reduces the gel 
to gel variation and enhances the quantitative accuracy as the test and reference samples 
are mixed and separated on the same single gel (Figure 9) [56]. However, time consuming 
is still the constraint of this technique. 
 
 1.3.2.2. Identification of the Proteins 
The identification of the protein of interest from the 2DE and DIGE could be performed 
by mass spectrometry (MS), which requires a smaller amount of sample material and 
have a higher throughput than the conventional sequencing methods. It functions through 
measurement of the charge-to-mass ratios of ionized molecules [58]. Matrix-Assisted 
Laser Desorption Ionization Time-of-Flight (MALDI-ToF) MS and Electrospray 
Ionization (ESI) are currently the most readily available technologies in protein 
identification. In MALDI-ToF MS, the peptides or proteins of interest are crystallized 
within a matrix with an absorption peak at a specific wavelength to allow energy from a 
laser to excite the matrix and ionize the proteins. The ionized peptides/proteins are then 
detected by ToF based on the charge-to-mass ratios where the smaller the ion, the faster it 
reaches the detector and be captured [58]. In ESI, a voltage placed on a fine needle causes 
a mist of fine droplets of charged particles which then allows the detection [58]. Before 
the identification of peptides by MS, the proteins of interest are removed from the 2DE 
gel and subjected to in-gel digestion, by trypsin, to obtain a mixture of peptides. The 
analysis on these digested peptides by MALDI-TOF MS provides a peptide mass 
fingerprinting (PMF) data set. This discriminative signature is compared with the peptide 
masses predicted from theoretical digestion of protein sequences currently contained 
within databases, and the selected protein from which the peptides were derived can be 
identified. The amino acid sequences of the protein can also be obtained by tandem mass 
spectrometry (MS/MS), in which discrete peptide ions can be selected and fragmented 
and complex algorithms are used to correlate the experimental data with corresponding 
data derived from peptide sequences in the protein database [50].  
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1.3.3. Non-Gel Based Proteomics Approaches 
1.3.3.1. Isotope Coded Affinity Tags (ICAT) 
Isotope coded affinity tags (ICAT) is a technology that utilizes stable isotope labeling to 
perform quantitative analysis of paired protein samples. Proteins or peptides are isotope 
labeled and unlike the gel-based proteomics approaches, the proteins are separated by 
liquid chromatography which are then subsequently identified by MS, as discussed in 
section 1.3.2.2.  The isotope tags used are similar in structure and chemical properties but 
are different in mass. The most popular isotopic tags are a set comprised of a light tag 
containing eight hydrogen atoms and a heavy tag containing eight deuterium atoms, 
making the mass difference of exactly eight mass units between these two tags [57]. 
Before the separation, the light and heavy tags are added into reference and test samples 
Figure 9: Workflow for DIGE technology.  The samples are separately attached with either Cy3 or Cy5 
and mixed before 2-dimensional separations on a single gel.  The individual image for the different 
samples can be obtained by scanning the gel at the specific wavelength for the Cy-dyes. The Cy3 and 
Cy5 images could be super-imposed overlaid to obtain a total protein differential map. In this case, if an 
overlapping spot appeared green, it represents higher expression in sample 2 and if the spot is red, then it 
is overexpressed in sample 1. The yellow overlapping spot demonstrated the same expression level of the 
protein in both samples. 
 respectively, and are specifically bound to the thiol-groups of the cysteine residues in the 
proteins. The two samples are then combined and digested by trypsin before subjecting to 
liquid chromatography and MS. The ratios of the isotopic molecular peaks that differ by 8 
Da, as revealed by MS, provides a measure of the relative amounts of each protein from 
the original samples (Figure 10) [57]. At the same time, the identification of the protein 
can be obtained through the PMF data sets. 
There are several advantages of this approach when compared to 2DE. It is not as time 
consuming and it allows proteins of low abundance to be detected, as higher amounts of 
the proteins can be analyzed in a single run [53]. Most importantly, accurate relative 
quantitation of the protein expression can be obtained through the differential labeling of 
different samples with light and heavy tags respectively. 
The main limitation of this technique is the labeling of the ICAT tag only to the amino 
acid, cysteine. Although most proteins contain cysteine but not all would, hence a small 
number of non-cysteine-carrying proteins are still not being tagged and thus not 
measured. In addition, the ICAT tag is a relatively large moiety. When it is tagged to a 
small peptide, it could interfere with the peptide ionization and complicate the mass 
spectral analysis. Nonetheless, ICAT still remains a powerful option as all these problems 


























1.3.3.2. Multidimensional Protein Identification Technology (MudPIT) 
Multidimensional protein identification technology (MudPIT) is an emerging proteomics 
technique interfacing two back-to-back liquid chromatographic steps (LC/LC) in a fused 
silica capillary to permit two-dimensional high performance liquid chromatography [56]. 
MudPIT incorporates high-performance liquid chromatography (HPLC, LC/LC), MS/MS 
and database searching algorithms to analyze the complex protein mixtures. The best 
combination of the LC before the analysis of MS/MS is the strong cation exchange (SCX) 
coupled to reverse phase (RP) chromatography. Firstly, the complex peptide mixture is 
loaded into the biphasic column for simultaneous separation and MS/MS analysis. The 
chromatography proceeds in steps with increasing salt concentration to selectively release 
proteins from the SCX resin into the RP resin. The RP reagent with increasing 
Figure 10: Schematic workflow of ICAT. The protein samples are first conjugated with heavy 
and light ICAT reagent respectively. The samples are mixed and digested with trypsin to obtain the 
peptides. The peptides were purified through an affinity chromatography and subjected to LC-MS-
MS analysis. The protein ID is predicted from the PMF using first stage MS and database search. 
Differences in protein expression in the two samples are determined by evaluation of the ratio of 
signal intensities for the light and heavy ICAT tagged to the specific peptides. 
 
 
 hydrophobicity is introduced to elute the peptides. The less hydrophobic peptides will be 
eluted earlier into the MS/MS where they are ionized and identified. The mass spectra 
generated are then matched to those in the database to identify the proteins (Figure 11) 
[56]. 
The advantage of the MuDPIT technique over 2DE is again, it is less time consuming and 
the whole process could be fully automated. The sample complexity could be greatly 
reduced with the fractionation of the sample through the two dimensional 
chromatography. This allows a greater number of peptides to be identified from a very 
complex mixture. The most prominent advantages of this technique are that the method 
has a wide dynamic range and there are no problems associated with protein solubility 
corresponding to those encountered as mentioned in 1.3.2.1.1. [53].  
Extremely complicated data collection and analysis are the primary limitations of this 
technique. The data is generated after 10-20 cycles of reversed phase chromatography in a 
single run. Hence powerful computing system and more time are required to complete the 
database search and to collate as well as assemble the data into an understandable format. 
However, with the rapid growth of more sophisticated computing resources coupled with 
greater affordability due to the lower costs, these main drawbacks of the MuDPIT 
platform can be overcome with careful planning. 
In summary, MudPIT represents a proteomic technique with great potential for the 












1.3.4. Cell-mapping Proteomics 
The cell mapping and global expression profiling are 2 contrasting but complementary 
strategies that have been very much employed in proteomics research [59]. The cell-
mapping proteomics or functional proteomics aims to define protein-protein interaction 
and to build a picture of complex networks that constitute intracellular signaling pathways 
[59] as this is of primary importance for an understanding of tumor growth and 
metastasis. Additional steps such as immunoprecipitation need to be performed prior to 
proteomics evaluation. For example, a group of researchers [59] had treated the Hela cell 
line with either epidermal growth factor (EGF) or platelet-derived growth factor (PDGF), 
and used the anti-phosphotyrosine immunoprecipitation to enrich a range of proteins that 
are subsequently being phosphorylated following stimulation by these growth factors. 
These analyses have successfully revealed the roles of many proteins in the signaling 
pathways triggered by EGF and/or PDGF. On the other hand, a target of interest in a 
Figure 11: Process of MudPIT technology. The proteins are digested into peptides and subjected 
to two dimensional liquid chromatography on strong cation exchange (SCX) coupled to a reverse-
phase (RP) column. Peptides are then fragmented by tandem MS and the protein of interest is 
identified through the database on the amino acid sequence obtained from MS/MS analysis. 
 signaling pathway could also be inhibited or stimulated before subjecting to specific 
protein enrichment and proteomic analysis to identify the associated proteins.  
 
1.3.5. Protein-expression Analysis 
Protein-expression analysis is a proteomics strategy to monitor the global expression of a 
large number of proteins within a cell type or tissue. It also quantitatively identifies how 
the pattern of expression changes under different circumstances [59]. Currently, this is the 
most widely used model of proteomics and it is largely dependent upon 2D gel 
electrophoresis. It is the equivalent of cDNA Microarray analysis which defines global 
patterns of RNA expression under various conditions. For instance, the expression of the 
proteins within matched normal and tumor tissues could be explored or the differentially 
expressed proteins between the untreated and treated cell lines could be assessed. 
In addition to expression profiling and protein-interaction mapping, many complementary 
tools have been developed to enhance the availability of functional proteomics methods. 
These include protein arrays, phage-display antibody arrays, surface enhanced laser 
desorption and ionization (SELDI)-based chips. Integration of data generated by these 
proteomics-based approaches with the data from genomics-based initiatives has led to 
major advances in cancer research and the translation of knowledge gained from such 
research into clinical practices. 
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1.3.6. Proteomics of Breast Cancer 
Research utilizing breast cancer proteomics tools have been focusing on the identification 
of differentially expressed proteins which might define the molecular and biochemical 
pathways involved in the malignant transformation of the normal breast tissues. These 
proteomics researches in breast cancer are part of the biomarker discovery process aiming 
to uncover the putative proteins within the ductal or lobular cells which would serve as 
biological markers and therapeutic targets for early detection of this cancer. 
 A study on DCIS revealed 57 proteins that showed differential expression between 
normal cells and DCIS [56]. The differential expression was predominantly due to 
differences in overall abundance. However there was also evidence that proteomics can 
be an effective tool in the study of post-translational modification of proteins in the 
Figure 12: Expression and cell-mapping proteomics. The expression proteomics involved the 
separation of proteins through 2DE. The protein of interest with differential expression between 
the paired samples can be selected and undergone MS analysis for protein identification. The cell 
mapping proteomics required additional steps such as immunoaffinity enrichment, affinity 
interaction to pull down the tag-protein and isolation of macromolecule complexes preceding the 
proteins separation through one dimensional electrophoresis.  
 malignant state, as displayed by the findings related to transgelin and the voltage 
dependent anion channel protein (VDAC) [56]. Furthermore, there was a subset of 
proteins including Annexin V and Hsp90 which had shown differential expression on 2D 
gels had been confirmed by IHC further provided assurance that the proteomics approach 
is sufficiently sensitive to be deployed for detecting clinically relevant changes.  
A potential breast cancer clinical markers identified through the proteomics studies is 14-
3-3 δ [7]. This protein had been shown to be easily detected on the 2D gels of normal 
breast epithelial cells using Coomassie stain but not in the breast cancer proteome profile 
when visualized under same staining method. Indeed, the much more sensitive silver 
staining was necessary for the observation of 14-3-3 δ on breast tumors suggesting it to be 
a strong marker for the cancer-free breast epithelial cell. This finding of 14-3-3 δ using 
proteomics has led to evaluation of its clinical usefulness in a clinical trial involving 400 
biopsies [7].  
A HER-2/neu overexpressed breast cancer cell line had also been investigated using 
proteomics techniques, DIGE,  to identify the proteins that are likely to be involved in 
HER-2/neu-mediated transformation [55]. The HER-2/neu overexpressed cell line was 
obtained through transfection of the parental HB4a cell line with a full-length normal 
human HER-2/neu cDNA. The expressed proteome of the transfected cells was compared 
to that of the parental strain. Eighteen proteins such as Hsp70 and aldolase reductase 
showing differential expression between the two cell lines were successfully identified. 
These proteins had been suggested to be implicated in the HER-2/neu-mediated 
transformation in a variety of ways [55]. 
The analysis of tumor tissues is always hampered by the problem of the heterogeneity of 
the tumor cells and other cells within the tumor nest. Laser capture microdissection 
(LCM) has thus been employed to procure a near pure population of malignant epithelial 
cells before the analysis. In a study performed to look into the potential molecular 
 mechanisms underlying why ER+/PR- tumors respond less well to tamoxifen as compared 
to ER+/PR+, LCM was employed to isolate the tumor cells from the frozen tumor tissues 
for 2DE analysis. The differential susceptibility to tamoxifen was suggested as a result of 
deregulated cytochrome b5-dependent metabolism [60]. 
Recent publications have demonstrated the value of cell mapping or functional 
proteomics in deciphering the intracellular signaling pathways. This is especially useful in 
the study of the effect of growth factor stimulation. The Fibroblast Growth Factor-2 
(FGF-2) is involved in the control of cell proliferation, differentiation, survival and their 
signaling pathways have been extensively described [7]. FGF-2 and its receptor had been 
reported to be overexpressed in a significant percentage of breast tumors, suggesting a 
key role in breast cancer growth and metastasis. When the proteomics analysis of the 
FGF-2 signaling pathway in the MCF-7 breast cancer cell line was performed [7], it was 
found that after FGF-2 stimulation, there was increased tyrosine phosphorylation of the 
FGF receptor, and increased expression of the FGF receptor substrate (FRS2), the 
oncogenic protein Src and the MAP kinases (p42/p44) [7]. Some of the proteins 
previously reported as showing up-regulation after FGF-2 treatment, such as the 
mitogenic factor PCNA, HSP 70 and HSP 90 which emerged as a wide-ranging group of 
molecular chaperones also showed consistent up-regulation [7]. This proteomics analysis 
of FGF-2 signaling in breast cancer cells thus permitted the revelation of rapid changes in 
protein phosphorylation and synthesis offering new information about the molecular basis 
of breast cancer cell growth. 
In summary, the proteomics-based-generated hypotheses and the emerging validation 
technologies, certainly open up new opportunities for uncovering the complete picture of 
molecular events involved in breast cancer progression. Effective and purpose-driven 
therapeutic targets for breast cancer could then be established leveraging on these 
proteomics results. 
 1.3.7. Clinical Diagnostic Applications of Proteomics  
The application of the proteomics approach is broad. It has been widely used to analyze 
cancer tissues such as squamous cells [61], lung [62, 63], liver [64] and so on. In a study 
of squamous cell carcinoma of the bladder, six squamous cell carcinomas were identified 
from 150 bladder tumors based on the unique two-dimensional proteome profile of this 
carcinoma [50]. Furthermore, a few of the identified proteins such as psoriasin, keratin 14 
and Galectin 7 [50] have been shown to be very useful in assessing the degree of 
differentiation. Psoriasin, in particular, has been identified as a potential urinary marker. 
In addition to cancer, human myocardial proteins had also been analyzed by proteomics 
tools. 2DE had been used to evaluate the proteins present in the human heart and the 
proteome in dilated cardiomyopathy [50].  These studies have contributed to the build up 
of human heart and dilated cardiomyopathy 2DE databases.  
In a recent study of the human heart left ventricle (LV) proteome, narrow range IPGs had 
been applied to improve the separation, especially of the proteins with isoforms, achieve 
higher resolution, and enable greater number of protein identification. The number of 
spots  detected on the composite gels was over two-fold greater than the number of spots 
detected on the same pH range with the 3-10 pH gradient and 110 proteins have been 
identified through MS/MS analysis [54]. 
Proteomics techniques have been also used in numerous studies of infectious diseases 
with the aim of searching for new diagnostic markers, candidate antigens for vaccines, 
and determinants of virulence. Mycobacterium tuberculosis is one of the microorganisms 
that has been extensively studied using proteomics. Several groups are characterizing the 
mycobacterial proteomes and several antigens that had been revealed from these studies 
have now been incorporated into trial vaccines [50].  
 
 
 2. Objective 
 
In the physiology of the breast, HER-2/neu is a key player driving its cellular functions by 
stimulating multiple signaling networks that are vital for cell differentiation and growth. 
However, its overexpression has led to profound detrimental consequences, which are 
clearly demonstrated by the unfavorable clinical outcomes manifested in breast cancer 
patients overexpressing HER-2/neu receptors. There is thus an imperative need to better 
understand of the molecular events associated with this receptor. 
 Much recent molecular research on HER-2/neu are predominantly focused on HER-
2/neu-linked signaling pathways. The most impressive results have been from studies 
utilizing HRG stimulation on breast cancer cell lines. Contemporary proteomics-based 
studies, on the other hand, are primarily concentrating on exploring the differential 
protein expression profiles between normal and breast cancer cells. To date, a number of 
differentially  expressed genes and proteins in HER-2/neu-positive breast cancer cell lines 
had been identified through cDNA microarray [65] and proteomics studies [55] 
respectively. However, none of the studies have yet looked at the protein expression 
patterns in HER-2/neu overexpressing breast cancer tissues excised from patients during 
lumpectomies, biopsies or mastectomies.  
Our project was initiated to study unresolved issues of HER-2/neu-mediated breast cancer 
by applying current proteomics technologies to breast tumors and matched normal breast 
tissues donated for research with informed patient consent to our hospital tissue 
repository. We aimed to: 
1. produce the proteome profiles of HER-2/neu-positive and -negative breast cancer 
subtypes using two dimensional gel electrophoresis (2DE),  
2. identify the differentially expressed proteins that are strongly associated with the 
HER-2/neu status, and  
 3. decipher the signaling networks associated with HER-2/neu based on the  proteins 
identified by the above studies. 
 3. Materials and Methods 
3.1. Materials 
3.1.1. Chemicals and Reagents 
The chemicals and reagents used in the project are listed according to the manufacturers, 
in Appendix A. 
 
3.2. Methods 
3.2.1. Clinical Specimens 
 
Ten HER-2/neu-positive and 15 HER-2/neu-negative frozen breast tumors were obtained 
from the Tissue Repository of National University Hospital (Singapore). The tissues were 
selected based on the prior data set acquired from a  tissue microarray (TMA) study of 97 
cases of breast cancer on the expression of the HER-2/neu receptor [40] using 
immunohistochemistry (IHC). All the breast tumors and matched normal tissues were 
obtained with patient consent and complied with the regulations set by our Institutional 
Review Board, such as anonymization to protect patient confidentiality issues. In order to 
ensure that HER-2/neu status remains the major discerning variable, those tumors that 
were chosen had also been controlled for other relevant pathological parameters, such as 
the histological type or grade (all of Grade 3), nodal status (all node-positive), and 
estrogen receptor (ER) content (all ER-negative). The proteins from a discrete number of 
well-matched tumors (3 or 4 per set) were pooled to minimize the misinterpretation of 
protein profiles arising from random differences in protein expression of different tumors 
and to obtain sufficient materials for downstream analyses. 
 
 3.2.2. Laser Captured Microdissection (LCM)  
3.2.2.1. Paraffin Embeddation of  Tissue Section for LCM 
The frozen tissues were fixed in 70% ethanol at 4ºC overnight. The ethanol-fixed tissue 
piece were trimmed to the appropriate dimension and fitted into the pre-cooled cassette 
within the tissue processor. Dehydration steps were performed by incubating the cassette 
with increasing concentration of ethanol, (70%, 80%, 95% and 100%) followed by 
xylene.  The tissues were then embedded in paraffin using the embedding molds. The 
paraffin blocks were then stored at 4°C until further use. The paraffin block then were cut 
into multiple 5mm thick sections using standard microtoming procedures.  
 
3.2.2.2. Hematoxylin Staining  
The cut sections were deparraffinized with xylene for 5min each twice and rehydrated 
with decreasing concentrations of ethanol (100%, 95% and 70%) and water for 10s each. 
The cut sections were stained in 10% hematoxylin in the presence of protease inhibitor 
cocktails (Complete Mini; Roche Molecular Biochemicals, Indianapolis, IN, USA), and 
dehydrated in xylene before LCM.  
 
3.2.2.3. Performing LCM 
Cells were microdissected using the PixCell II LCM System (Arcturus Engineering, 
Mountain View, CA, USA) with 10 000 shots, corresponding to 50 000–70 000 cells, 
within the set maximum time period of 30 min per slide. The malignant epithelial cells 
were differentiated from normal cells within the tumor nest microenvironment by direct 
microscopic visualization, and microdissected according to the manufacturer’s instruction 
after hematoxylin staining. 
 
 
 3.2.3. Protein Extraction 
3.2.3.1. LCM Procured Tumor Cells 
The microdissected cells collected in the cap were lysed in a 40mM Tris-HCl buffer (pH 
7.0) containing 7M urea, 2M thiourea, 4% CHAPS, 1% Mega-10, 0.5% Triton X-100, 
50mM DTT, 1% IPG buffer (pH 3–10) and 2mM tributylphosphine. The samples were 
vortexed vigorously to ensure complete lysis of the cells and centrifuged at 14 000 x g for 
10 min. The proteins (supernatant) were transferred to a new microcentrifuge tube. 
 
3.2.3.2. Fresh Frozen Tumor Tissues 
Frozen aliquots of pre-selected tumor tissues were immersed in liquid nitrogen and 
ground into powder form with a pestle. The cells were lysed in 250–350µl of lysis buffer 
(Reagent 1) from the Sequential Extraction Kit (Bio-Rad, Hercules, CA), supplemented 
with 1U of DNase and protease inhibitor cocktails (Complete Mini, Roche). The sample 
mixtures were incubated on ice, vortexed vigorously every 10 min for 1 hr and 
centrifuged for 20 min at 16 100 x g, 4°C to remove the cell debris. The supernatant was 
transferred into a new tube and 100% acetone was added to the supernatant at four times 
sample volume and incubated overnight at -20°C for protein precipitation. The 
precipitated proteins were washed two times with acetone:water (4:1) before 80-150µl of 
sample solution containing 8M Urea, 4% CHAPS, 60mM DTT and 2% IPG buffer (pH 3-
10) was added. The actual volume added being adjusted according to the pellet size, to 
dissolve the protein. The protein samples were kept at -80ºC until further use. 
 
 3.2.4. Buffer preparation 
Tables 1, 2 and 3 show the composition of the rehydration buffer, the equilibration buffer 
and the electrophoresis running buffer. 
 
 Table 1: The composition of rehydration buffer. 
 Final Concentration Amount 
Urea 8M 4.8g 
CHAPS 2% 0.2g 
Bromophenol blue (BPB) 0.002% (w/v) 50µl of 1% (w/v) BPB 
Milli-Q water (Millipore, 
Bedford, MA, USA)  to 10ml 
   Note: Solution was stored in 1ml aliquots at -20°C 
 17.4µl of 200mg/ml of DTT and pH matched IPG buffers (0.5% to 1%) were 




Table 2: Preparation of equilibration buffer. 
 Final Concentration Amount 
Tris-HCl, pH8.8 50mM 10ml 
Urea 6M 72.07g 
Glycerol (87% v/v) 30% (v/v) 69ml 
SDS 2% 4g 
BPB 0.002% (w/v) 400µl of 1% (w/v) BPB 
Milli-Q water  to 200ml 
 
 
Table 3: The composition of 1X SDS electrophoresis running buffer. 
 Final Concentration Amount 
Tris-base 25mM 3.03g 
Glycine 192mM 14.40g 
SDS 0.1% (w/v) 1.0g 
Milli-Q Water  to 1L 
 
 3.2.5. Casting of Denaturing Polyacrylamide Gels 
The compositions of the resolving and stacking gels are shown in Tables 4 and 5. 
 
Table 4: The compositions for the preparation of 10% and 12% resolving gel. 
  10% (ml) 12% (ml) 
30% acrylamide mix (29:1) 33 40 
1.5M Tris-HCl, pH 8.8 25 25 
10% SDS 1 1 
10%APS 0.50 0.50 
TEMED 0.05 0.05 
Milli-Q water 40.45 32.95 
Total volume 100 100 
 
Table 5: The ingredients for the preparation of stacking gel at 4% acrylamide. 
 10% (ml) 
30% acrylamide mix (29:1) 1.320 
1.0M Tris-HCl, pH 7.0 2.500 
10% SDS 0.100 
10% APS 0.050 
TEMED 0.005 
Milli-Q water 6.025 
Total volume 10 
 
 
3.2.6. Sample Preparation for Two-Dimensional Gel Electrophoresis (2DE) 
The extracted proteins were cleaned up using the PlusOne 2-D Clean-up Kit (GE 
Healthcare, San Francisco, CA, USA) according to the manufacturer’s instructions, to 
remove the interferences during the 2-DE. The protein concentrations were determined 
using Coomassie PlusTM Protein Assay Reagent (Pierce, Rockford, USA). This reagent 
was a modified Bradford method that is capable of tolerating the high concentration of 
urea (8M) in the sample solution used for dissolving the extracted protein pellet. Briefly, 
the sample was diluted 10 times with water. The absorbance was obtained after blanking 
and the concentration of the sample was estimated from the calibration curve constructed 
with known concentrations of bovine serum albumin (BSA). All of the protein samples 
were stored at -80°C until use.   
 3.2.7. 2DE: First Dimension- Isoelectrical Focusing (IEF) 
The extracted proteins of HER-2/neu-positive and HER-2/neu-negative tumors were 
pooled to obtain 90 µg or 150 µg of total proteins. The protein separation at first 
dimension was performed using precast 18 cm Immobiline IPG dry-strip (GE Healthcare, 
Uppsala, Sweden) available in three different pH ranges (pH 3-10NL, pH 4-7 and pH 6-9) 
on EttanTM IPGphorTM Isoelectric Focusing System (GE Healthcare, Uppsala, Sweden). 
In-gel rehydration loading was performed for the protein separation on IPG dry-strip pH 
3-10NL and pH 4-7. 150µg of pooled proteins were first separately mixed and rehydrated 
with 340µl rehydration buffer containing 7 M urea, 2% CHAPS, 3.5mg DTT and 1% of 
pH-matched IPG buffer. On the other hand, anionic cup loading was applied for 
separation on IPG dry-strip pH 6-9. The strips were rehydrated with rehydration solution 
without addition of samples but containing 15mg of hydroxyethyl-disulfide (HED) 
reagent (DeStreak, GE Healthcare, Uppsala, Sweden) in lieu of DTT. 90µg of the samples 
were then applied through anionic cup loading for separation according to the instruction 
manual by GE Healthcare. The optimized conditions for IEF are summarized in Table 6. 













1 Step & Hold 500 1:00 0.5 
2 Step & Hold 2000 1:00 2.0 




12 hr  
20V 
4 Step & Hold 8000 6:00 48.0 
1 Step & Hold 300 1:30 0.45 




12 hr  
 20V 
3 Step & Hold 8000 5:00 40 
1 Step & Hold 500 0:03 0.015 






3 Step & Hold 8000 6:53 55 
*Rehydration Loading: IPG dry-strip rehydrated in 340µl of rehydration buffer   
containing sample.    
Cup Loading: IPG dry-strip rehydrated in 340µl of rehydration buffer without sample. 
 
 
3.2.8. 2DE: Second Dimension- SDS-PAGE Electrophoresis 
The IPG strips were first equilibrated for 20 min in a buffer containing 50mM Tris-HCl, 
pH 8.8, 30% glycerol, 7M urea, 2% SDS and 100mg DTT, followed by further treatment 
in a similar buffer containing 250mg iodoacetamide instead of DTT for 20 min. The SDS-
PAGE gels were prepared according to the formulation at Table 4. 12% homogeneous 
SDS-PAGE gels were first determined to provide the best separation for the proteins. 
Thus, the IPG dry-strips were directly applied on to 12% homogeneous SDS-PAGE gels 
for electrophoresis using a PROTEAN II xi Cell system (Bio-Rad, Hercules, CA, USA) at 
15 mA for the first two hours and 45 mA until the dye front reached the edge of the gels.  
 
 3.2.9. Image Visualization: Silver Staining 
The gels were stained in 400ml of the appropriate solution according to the steps listed in 
Table 7. All the steps were performed at room temperature with constant shaking. This 
protocol was modified from PlusOne Silver Staining Kit (GE Healthcare, Uppsala, 
Sweden). The incubation time (1hr) for the sensitization step was determined to be the 
optimal after incubation at different durations had been tested. The sensitization solution, 
silver nitrate and developing solution were prepared fresh and filtered before use. 
 
Table 7: The Solutions and steps for performing silver staining. 
Step Reagents Duration 
Fixing 
40% (v/v) ethanol 
10% (v/v) acetic acid 
1 hr 
Sensitization 
30% (v/v) ethanol 
6.8% (w/v) sodium acetate 
0.002% (w/v) sodium thiosulphate 
1 hr 
Washing Milli-Q Water 3 x 15 min 
Staining 0.25% (w/v) silver nitrate 1 hr 
Washing Milli-Q Water 2 x 2 min 
Developing 
2.5% (w/v) sodium carbonate 
40µl of 37% formaldehyde 
to every 100ml of solution 
Terminated when the 
desired intensity had been 
acquired 
Stopping 5% (v/v) acetic acid 3 min 
Storing 
1% (v/v) acetic acid 
10% (v/v) methanol 
4ºC until next analysis 
 3.2.10. Image Acquisition and Analysis 
The image acquisition was performed with a Personal Densitometer SI (Molecular 
Dynamics, Sunnyvale, CA, USA). ImageMaster 2D Elite (GE Healthcare, Uppsala, 
Sweden) software was used for the analysis of the proteome profile generated using the 
IPG dry-strip of pH 3-10NL. Subsequent proteome profiles obtained for pH 4-7 and pH 
6-9 conditions were analyzed using ImageMaster 2D Platinium software (GE Healthcare, 
Uppsala, Sweden). The image analysis includes spot detection and edition, normalization 
of the spot intensities to the background interferences and quantification of the spot 
intensities. Proteome profiles of the pooled HER-2/neu-positive and HER-2/neu-negative 
samples were then matched and compared. Only the spots which showed either more than 
two-fold or less than two-fold changes in intensity from three replicate analyses were 
selected for protein identification by MS. 
 
3.2.11. Trypsin Digestion and MS 
All the spots showing significant differential expression were picked and in-gel digested 
manually. First, silver-stained protein gel spots were destained with 30mM potassium 
ferricyanide and 100mM sodium thiosulfate (1:1) which were then rinsed with Milli-Q 
water to stop the destaining reaction. The gel spots were then incubated with 25mM 
sodium bicarbonate for 20min after which the gel spots were cut into smaller pieces. The 
gel pieces were then rinsed three times with Milli-Q water and dehydrated in 50mM 
sodium bicarbonate / 50% v/v methanol and dried in a SpeedVac centrifuge (TeleChem 
International, Incorporation, Sunnyvale, CA, USA). The dried gel pieces were reswelled 
with 10-20µl of digestion solution containing 20mM ammonium bicarbonate and 40ng/µl 
sequencing grade trypsin (Promega, Madison, WI, USA). The tryptic digestion of the 
proteins was carried out at 37ºC overnight. The resultant hydrophilic peptides were first 
extracted with 10µl Milli-Q water for 1hr followed by hydrophobic peptides extraction 
 with 5% v/v Trifluroacetic acid (TFA) in 50% v/v acetonitrile (ACN) for 2hr. The 
extracted hydrophilic and hydrophobic peptides were pooled and dried in SpeedVac 
centrifuge, and redissolved in 10µl of 0.1% v/v TFA. The samples were desalted with 
ZipTip C18 columns (Millipore, Bedford, MA, USA) and eluted with 2.5µl of 50% v/v 
ACN containing 0.1% TFA. The digested peptides were sent for MS analysis provided at 
the Protein and Proteomics Centre, National University of Singapore, Singapore. Briefly, 
the samples, after being mixed thoroughly with 3mg/ml of α-cyano-4-hydroxycinnamic 
acid (CHCA) matrix were spotted onto stainless steel MALDI sample target plates, and 
placed in the sample chamber of Applied Biosystems 4700 Proteomics Analyzer MALDI-
TOF/TOF mass spectrometer (Applied Biosystems, Framingham, MA, USA). The 
peptide mass spectra were generated by the above system, programmed in the positive ion 
reflector mode. The subsequent MS/MS analysis was performed in a data-dependent 
manner and the ten most abundant ions fulfilling certain preset criteria were subjected to 
high energy CID analysis. The collision energy was set to 1keV, while nitrogen was used 
as the collision gas. 
 
3.2.12. Database Search 
Known contamination peaks such as keratin and autoproteolysis peaks were removed 
prior to a protein mass fingerprint database search with MASCOT software (Matrix 
Science, London, UK) in the NCBInr database. Up to one missed tryptic cleavage was 
considered and a mass accuracy of 50ppm was used for all tryptic-mass searches and 
within 0.5Da for CID experiments. Searches were performed without constraining protein 
molecular weight (Mr) or isoelectric point (pI) and species, and allowed for 
carbamidomethylation of cysteine and partial oxidation of methionine residues. Protein 
scores greater than 75 is considered as significant (p<0.05). Further confirmation of 
 protein identifications was obtained by duplicating the protein identification using the 
MS-Fit software (http://prospector.ucsf.edu). 
 
3.2.13. Western Blotting and Immunodetection  
Proteins were separated on 10-12% SDS-PAGE gels using Mini-PROTEAN 3 
Electrophoresis Cells (Bio-Rad, Hercules, CA, USA) at 70V for 30min and 85V until the 
dye front reached the edge of the gel. The proteins were transferred onto Hybond-P 
Polyvinylidene Fluoride (PVDF) membrane (GE Healthcare, Little Chalfont, Bucks, UK) 
using the wet apparatus (Bio-Rad, Hercules, CA) at 110V for 1hr. The membranes were 
blocked with 5% non-fat milk in Tris-buffered saline containing 0.1% Tween-20 (TBS-T) 
and incubated overnight with the respective antibodies to be tested at 4ºC. The antibodies 
that have been tested with the appropriate dilutions in 5% milk/TBS-T were mouse-anti 
cytokeratin 19 (CK19) (1:500; NeoMarkers Inc., Fremont, CA, USA), mouse anti-fatty 
acid synthase (FASN) (1:500; BD Biosciences Pharmigen, USA), mouse anti-Heat shock 
protein 27 (Hsp27) (1:1000; Santa Cruz Biotechnology, Inc, Europe), goat anti-
phosphoglycerate kinase 1 (PGK1) (1:500, Santa Cruz Biotechnology, Inc, Europe), 
rabbit anti-glyoxalase (1:500; kindly given by Dr KD Tew from the Institute of Cancer 
Research, University of London), mouse anti-BiP/Glucose related protein 78 (GRP78) 
(1:500; BD Biosciences, Pharmingen, USA), rabbit anti-heterogeneous nuclear 
ribonucleoprotein H1 (hnRNPH) (1:5000; US Biological, Massachusettts, USA), mouse 
anti-Raf kinase inhibitor protein (RKIP) (ZYMED Laboratories Inc. San Francisco, CA, 
USA) and horseradish peroxidase (HRP)-conjugated mouse anti-β-actin  (1:500; Santa 
Cruz Biotechnology, Inc, Europe). One of the following secondary antibodies – the HRP-
conjugated goat anti-mouse IgG (Molecular Probes, Invitrogen, Oregon, USA) at 1:5000 
dilutions in TBS-T, HRP-conjugated goat anti-rabbit IgG (ZYMED Laboratories Inc. 
San Francisco) at 1: 10 000 dilutions in TBS-T, or HRP-conjugated mouse anti-goat IgG 
 (ZYMED Laboratories Inc. San Francisco, CA) at 1: 10 000 dilutions was applied for 1 
hr after washing off any unbound primary antibodies. The chemiluminescent signals were 
detected using SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, 
USA). Signals were captured with the MULTI GENIUS BioImaging System (Syngene, 
Frederick, MD, USA) and the signal intensities were analyzed using the GeneTools 
software (Syngene, Frederick, MD, USA). The same membrane was reprobed with 
antibody for β-actin to control for protein loading and transfer. 
 
3.2.14. 2D Immunodetection 
 For 2D immuno-detection, the same protein samples used for the protein profile analysis 
were tested. The pooled proteins were first separated using precast 7 cm Immobiline IPG 
dry-strip (pH 3-10, pH 3-5.6 or pH 4-7) (GE Healthcare, Uppsala, Sweden). In-gel 
rehydration with 20 µg or 40 µg of proteins was applied for the IEF.  The IEF running 
conditions are summarized in Table 8. 
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 The proteins on the IPG dry-strip were then further separated by 10 or 12% SDS-PAGE 
using Mini-PROTEAN 3 Electrophoresis Cells (Bio-Rad) and electro-transferred onto 
PVDF membranes by the wet apparatus (Bio-Rad) at 110 V for 1 hr. The membranes then 
were blocked with 5% non-fat milk/TBS-T for 1hr and were separately probed with one 
of the following primary antibodies: mouse anti-CK19 (1:500; NeoMarkers), mouse anti-
FASN (1:500, BD Biosciences), mouse anti-Hsp27 (1:1000, Santa Cruz Biotechnology, 
Inc), goat anti-PGK1 (1:500, Santa Cruz Biotechnology, Inc), rabbit anti-GLO (1:500, 
kindly given by Dr KD Tew from Institute of Cancer Research, University of London), 
mouse anti-BiP (1:500; BD Biosciences, Pharmingen), rabbit anti-hnRNPH1 (1:5000; US 
Biological) and mouse anti-RKIP (ZYMED Laboratories Inc.). One of the following 
secondary antibodies – HRP-conjugated goat anti-mouse IgG (Molecular Probes, 
Invitrogen) at 1:5000 dilutions in TBS-T, HRP-conjugated goat anti-rabbit IgG  
(ZYMED Laboratories Inc.) at 1: 10 000 dilutions in TBS-T or HRP-conjugated mouse 
anti-goat IgG (ZYMED Laboratories Inc.) at 1: 10 000 dilutions – was applied for 1 hr 
after washing of the primary antibodies. The chemiluminescent signals were detected 
using SuperSignal® West Pico Chemiluminescent Substrate (Pierce). Signals were 
captured with the MULTI GENIUS Bio Imaging System (Syngene) and the signal 
intensities analyzed using the GeneTools software (Syngene). 
 
3.2.15. Immunohistochemistry on Tissue Microarray (TMA) Sections 
Immunostaining of Tissue Microarray (TMA) sections was carried out as described 
previously [66, 67]. Briefly, sections were deparaffinized in xylene and rehydrated in 
graded alcohols. Antigen retrieval, endogenous peroxidase block and Envisionplus 
detection were performed with the Dako Envision1 system (Glostrup, Denmark). The 
primary antibody for CK19, FASN, GLO, PGK1 and Hsp27 was applied separately to 
 different sections at room temperature for 60 min, followed by detection with labeled 
dextran polymer conjugated with peroxidase and DAB1-substrate chromagen solution. 
The extent of staining was scored by a pathologist and a research scientist independently, 
according to the percentage of positive cells as follows: 0, less than 5% of tumor cells 
were positive; 1, 5–24% were positive; 2, 25–74% were positive and 3, more than 75% 
were positive. Cases with discrepant scores were rescored by the same or additional 
scorers, in order to obtain a consensus score. All the sections were examined without 
prior knowledge of the clinical information for any of the cases. 
 
3.2.16. Statistical Analysis 
A Fisher’s exact test was used to compare the expression of CK19, FASN, Hsp27, PGK1 
and GLO between HER-2/neu-positive and –negative tumors on the TMA. A p value 
(two-sided) of 0.05 was considered statistically significant. 
 4. Results 
4.1. Proteome Profiling and Protein Identification 
4.1.1. Proteome Profiles of pH 3-10NL 
Total soluble proteins extracted from tumor cells after dissecting with LCM were pooled 
to obtain sufficient materials. The 2D images of HER-2/neu-positive and -negative tissues 
at pH 3-10NL were then obtained from the respective pooled samples. The 2D images of 
HER-2/neu-positive and -negative tissues obtained were matched and analyzed by Image 
Master Elite (GE Healthcare). There were about 500-600 protein spots being detected and 
the relative intensity of each spot was acquired through the software. Thirty spots with at 
least two-fold differences in intensities in all the three replicates of 2D images after Image 
Master software analysis and manual comparison of the spot intensities on the original 
gels were selected for MS/MS analysis. 
Seventeen spots had been unambiguously identified through MALDI-ToF MS analysis. 
The Mascot score, sequence coverage and differential expression level as well as the 
biological functions of the proteins were summarized in Table 9. Figures 13 and 14 
displayed the proteome profiles generated and the enlarged images of the identified 
proteins respectively. The identified proteins included a stress-related protein, (heat-shock 
protein 27 [Hsp27]), six proteins associated with intermediary metabolism (triose-
phosphate isomerase [TPI], phosphoglycerate kinase 1 [PGK1], enolase 1 [ENO1], fatty 
acid synthase [FASN], aldolase A and cathepsin D), four proteins with antioxidant and 
detoxification functions (haptoglobin, β-subunit of prolyl-hydroxylase [P4HB], 
glyoxalase I and aldo-keto reductase [AKR]), two structural proteins (cytokeratin 19 
[CK19] and tropomyosin 3) and a nuclear receptor interaction protein. However, there 
were 3 proteins (manganese superoxide dismutase [MnSOD], albumin, and selenium 
binding protein) demonstrating lower expression in HER-2/neu-positive tissues. 









































Selenium binding52.9/6.8172Selenium Binding Protein 117
Protein carrier47.4/6.092Albumin15
Nuclear receptor interaction27.3/8.867Nuclear receptor interaction protein 316
Muscle contraction32.9/4.7597Tropomyosin 312
Glycolysis39.4/8.3116Aldolase A1


























Structural organizationCytokeratin 19 (CK 19)14
Steroid hormone metabolismAldo-keto reductase (AKR)13
Protein folding and assemblyProlyl 4-hydroxylase, β-subunit (P4HB)11
Hemoglobin bindingHaptoglobin10
Fatty acid synthesisFatty acids synthase (FASN)9
GlycolysisPhosphoglycerate kinase I (PGK1)8
GlycolysisEnolase 1 (Phosphopyruvate hydratase)7
Redox regulationsGlyoxalase I6
GlycolysisTriose-phosphate isomerase (TPI)5
Protein folding and assemblyHeat-shock protein 27 (Hsp27)4
Proteolytic enzymeCathepsin D (Chain 3)3
Protein FunctionsProtein IDSpot 
Table 9: Summary of the identified proteins. The differentially expressed spots (more or less than two-fold) on the 2D gels were 
excised, in-gel digested and MALDI-ToF MS analysis was performed. The protein identification was obtained through the database 
search based on the peptide mass fingerprinting (PMF). There were 17 proteins successfully being identified. Protein ID with Mascot 








           
Figure 13: Proteome profiles for microdissected tumor tissues.  The respective proteins 
extracted from microdissected HER-2/neu-positive and -negative cells were separated across pH 3-
10NL as shown by the above representative pair of images. There were 500-600 spots being 
visualized after silver staining. The highlighted spots were the spots selected for MS analysis and 
identification by reference to existing proteome databases. 
Figure 14: Enlarged images of the identified spots. Seventeen spots with Mascot scores of more 
than 75 were identified through NCBInr search.  
 
 
 4.1.2. Proteome Profile of pH 4-7 
Due to limited source of tissue sections and the difficulties in procuring sufficient amount 
of homogeneous cell type for the protein extraction, the proteome profiles for pH 4-7 
were acquired from a fresh batch of tumor tissues. Subsequent silver staining and Image 
Master Platinium (GE Healthcare) analysis had revealed 800-1000 spots on each gel 
(Figure 15). Comparison and statistical analysis of the paired proteome profiles (HER-
2/neu-positive vs –negative tumors) by the Image Master Platinium software recognized 
about 80 spots showing more than two-fold changes in the intensity. Of these, 16 spots 
were indisputably identified after MALDI ToF/ToF MS/MS analysis and database search. 
Figure 15 and 14 demonstrated the proteome profiles highlighting the 16 identified spots. 
The characteristics of the protein identified including the molecular weight and pI, 
number of matched peptides, MS/MS spectrum, sequence coverage and Mascot score as 
well as the relative spots intensity were listed in Table 10 and 11. Six of the identified 
proteins demonstrated increased expression in HER-2/neu- positive tissues. These include 
tropomyosin 1(α), cytoplasmic actin, cytokeratin 10 (CK10), apolipoprotein A-1 (Apo A-
1), Glutathione-S-transferase (GST) and heterogeneous ribonucleoprotein H1 
(hnRNPH1). There were five proteins showing decreased expression in HER-2/neu-
positive tissues. These proteins had been known to be Bip/Glucose Related Protein 78 
(GRP78), calreticulin precursor variant, galectin 1, transferrin and peroxiredoxin isoform 
3. Four proteins (regucalcin, aldo-keto reductase family 1 member 2 variant, superoxide 
dismutase (SOD) and Heat shock protein 70 (Hsp70) protein 9B) were only noticeable in 
HER-2/neu-negative tissues and one protein, (SH3 domain binding glutamic acid rich 






























































































Figure 15: Proteome profiles of pH4-7.  The total proteins extracted from the tissues were 
separated across pH 4-7 at the first dimension followed by SDS-PAGE. About 800 to 1000 spots 
were detected with silver staining. The spots showing significantly differential expression were 
picked for the protein identification. 16 highlighted spots were identified from the database. 
Figure 16: Enlarged images of the identified spots. 16 spots with substantial differential 
expression between two subtypes of tumors were highlighted. These proteins scored above 75 for 
the Mascot analysis and thus had been confidently identified. 
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Detected only in HER-2/neu Negative242413216.2/5.738489880Superoxide dismutase (SOD)5
-2.50222118855.2/6.0553788Transferrin13
-2.00443914826.1/7.0432483377Peroxiredoxin 3 Isoform B8





Detected only in HER-2/neu Negative4531215033.2/6.8662087614Aldo-keto reductase 
familily 1 member 2 variant
7
3.672731125149.4/5.7948145673Heterogeneous nuclear 
ribonucleoprotein H1 (HnRNP H1)
15
2.202621317359.0/5.0921961605Cytokeratin 10 (CK 10)16










2.474651923430.7/5.56Apolipoprotein A-1 (Apo A-1)6
Detected only in HER-2/neu Negative3151520733.8/5.89Regucalcin3














Table 10: Summary of the identified proteins.  After the matching of the proteome profiles of HER-2/neu-positive and -negative tumors 
by the Image Master software, the differentially expressed proteins were selected for MS/MS analysis after in-gel digestion. There were 
16 proteins that were successfully being identified with Mascot scores more than 75. 















































































































Table 11: Summary of MS/MS analysis. The Mascot score was the probability study of the Mascot program where only score above 75 would be considered 
significant. The MS spectrum was obtained after ionization and detection of the digested peptides based on charge-to-mass ratio. Peptides meeting the pre-set 
criteria would be selected on-line and fragmented for analysis by second MS. The distinctive amino acid sequences could be then obtained and allowed database 
search of the protein ID. The peptide fragmentation spectra shown here represent one of the many selected peptides for each protein being identified.  
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 4.1.3. Proteome Profile of pH 6-9 
The identification of the alkali protein had been performed with the separation of the 
proteins extracted from the fresh tissues through pH 6-9 at the first dimension. 
Approximately 300-400 spots were visualized after silver staining. Alkali proteins were 
present at a lower level as compared to acidic protein (800-1000 spots). This concurred 
with the profiles created across pH 3-10 where more spots were observable and identified 
at the acidic side (left) of the proteome profile. Six proteins were identified out of twenty 
five spots showing differential expression when the proteome profiles were matched and 
analyzed using Image Master Platinium software (GE Healthcare) and MS/MS (Table 12 
and 13). Figure 17 and 18 displayed the representative proteome profiles generated with 
the identified proteins highlighted and the enlarged image of the identified proteins 
respectively.  
The majority or five of the six identified had increased expression in HER-2/neu-negative 
tissues. Only one spot showing a higher expression level was confirmed in HER-2/neu-
positive tissues despite the fact that many of the spots selected (yellow circles in Figure 
18) for MS/MS analysis had appeared to demonstrate up-regulation in HER-2/neu-
positive tissues. This was due to contamination of the sample with keratin though 
precautionary steps such as consistent changing of gloves, wearing of face masks, 
working in clean and isolated area were taken during in-gel digestion.  
The five identified proteins that were overexpressed in HER-2/neu-negative tissues 
included aldo-keto reductase family member B2 and C2, annexin isoform 2, flavin 
reductase (NADPH) and Raf-1 kinase inhibitor protein (RKIP). On the other hand, the 
only one protein that was overexpressed in HER-2/neu-positive tissues was aldolase A.  






































-2.003838.7/7.6Annexin A2 isoform 24
-2.004037.1/7.13Aldo-keto reductase family 1 member C23
















Table 12: Summary of the identified proteins. Six of the differentially expressed proteins on the 2D gels were identified after 
MS/MS analysis and database search based on the peptide sequences. The peptide sequences of these six proteins calculated to have 
Mascot score of more than 75 thus confirming their ID. 
 


















































































































Table 13: The MS/MS analysis. The Mascot scores and spectrums of the MS/MS for the six identified proteins were shown. The MS spectrum 
based on the-mass-to-charged ratio of the tryptic digested peptides allowed selection of the best fragments for further analysis by the tandem MS. 
The study of selected peptides provided the unique amino sequence for the database search of the ID. The protein functions were listed as a 
reference. 
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Figure 18: Enlarged images of identified spots.  The spots that had been selected for the 
protein identification had clearly demonstrated to have differential expression in this enlarged 
image. Most of the identified proteins had showed higher level in HER-2/neu-negative tissues 
(Spot 1, 2, 3, 4 and 6). The yellow highlighted spots were among the spots that were 
overexpressed expressed in HER-2/neu-positive tissues but the identification through MS/MS 
analysis was unsuccessful. 
Figure 17: 2D images of the alkali proteins. The alkali proteins were separated across pH 6-9 
with modifications to the procedures for the separation of pH 3-10 and pH 4-7. The proteins were 
applied through cup loading during the IEF and destreak reagent was used instead of DTT during 
the separation. The spots were visualized after silver staining and about 300-400 spots were 




 4.2. Functional Grouping of the Identified Proteins 
The biological functions of the identified proteins had been studied based on the previous 
works done to permit better understanding of the roles of the proteins in the progression 
of the breast cancer associated with the HER-2/neu status. The specific functions of the 
proteins were listed on Tables 9, 11 and 13. In Table 14, the proteins identified by the 
expression proteomics studies were grouped under eight clusters based on the previously 
reported biological functions. Figure 19 illustrates that two largest clusters were proteins 
involved in intermediary metabolic pathways (10 of 38 or 26%) and transportation (9 of 
38 or 24%). The other clusters, with 5 proteins in each, were variously involved in 





















Figure 19: Evaluation on the functional groups. The functional groups were analyzed by 
numerical representation to assess the relative ‘contribution’ of each functional group in the 
development of the breast cancer. Proteins involved in intermediary metabolisms might be the key 
role players in the HER-2/neu-mediated breast cancer. 
  
Functional Group Protein 
 
Structural Proteins 
     Tropomyosin 1(α) and 3 
     Actin, cytoplasmic 
     Cytokeratin 10 (CK10) 





Catalytic Enzymes in             
Intermediary 
Metabolisms 
     Aldolase A 
     Triose-phosphate Isomerase (TPI) 
     Enolase 1(ENO1) 
Phosphoglycerate kinase I (PGK1) 
     Fatty acid synthase (FASN) 
     Aldo/keto reductase family members (AKRs) 






Transporter / Binding /       
Adapter  Proteins 
     Apolipoprotein A-I 
     SH3 domain binding glutamic acid-rich protein 
     Transferrin 
     Haptoglobin 
Albumin 
     Nuclear receptor interaction protein 
     Selenium Binding Protein 1 
     Annexin A2 isoform 2 
     Galectin 1 




     Heat-shock protein 27 (Hsp27) 
     Prolyl-4-hydroxylase (PH4B) 
     Bip/GRP 78 
     Calreticulin precursor variant 
     Hsp70 protein 9B 
     
RNA Processing     Heterogenous nuclear ribonuclearprotein H1 (hnRNPH1) 
Proteolytic Enzymes      Cathepsin D 
Signaling Suppressor                        
Proteins 
Raf-1 kinase inhibitory protein (RKIP) 




    GST 
    Peroxiredoxin 3 isoform B 
    Manganese superoxide dismutase (MnSOD) 
    SOD 
    Glyoxalase I 
 
 
Table 14: Functional Grouping of the proteins. There were eight functional groups 
being identified after the evaluation on the function of the proteins. 
 4.3. Validation of the Protein Expression 
4.3.1. Cytokeratin 19 (CK19) 
CK19 was found to be 7.5 fold increased in HER-2/neu-positive tissues through the 2D 
image analysis (Figure 13; Spot 14). Western blotting further confirmed that expression 
of CK19 was higher in the HER-2/neu-positive tumors (Figure 20) based on the average 
relative expression of CK19. 
2D immunoblotting was also carried out as alternative form of result verification for 
CK19 expression. The proteins were first separated across pH4-7.  However, due to its 
high abundance and its many isoforms with pIs within a narrow range, CK19 isoforms 
could not be well discriminated across pH 4-7. A different IPG dry-strip with a narrower 
pH range (pH 3.6-5) was used to allow better separation of all the isoforms. Figure 21 
shows the improper separation of CK19 across pH 4-7 where all the isoforms clustered as 
one big spot. With the separation on pH 3.6-5, two of the isoforms (yellow circles) had 
migrated apart from the group. Unfortunately, the remaining isoforms in the large cluster 
of CK19 remained indistinguishable, even with the narrow pH range. Based on the total 
spot intensity, HER-2/neu-positive tissues demonstrated a higher expression compared to 
HER-2/neu-negative tissues thus confirming our proteomics results. 
An IHC analysis was carried out on replicate section of a TMA containing 97 tumors and 
matched normal cohorts. Of these 78 arrayed tumors, with scoreable results, were 
subjected to statistical assessment. CK19 was found to be strongly associated with the 
HER-2/neu status (P=0.002). As shown in Figure 22, there were 15 out of 26 cases (58%) 
of HER-2/neu-positive tissues showing strong cytoplasmic staining, and 6 (23%) showing 
moderate staining. In contrast, there were only 10 cases (19%) of HER-2/neu-negative 
tissues showing strong staining and 30 cases (58%) with weak staining. These results 
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Figure 20: Expression of CK19 in breast cancer tissues. The expression ok CK19 was 
tested using Western Blot. 15µg of total protein from each case was loaded. Monoclonal 
antibody against CK19 was used for detection and β-actin was detected as loading control. 
The average relative expression demonstrated that CK19 expression was 3 fold higher in 
HER-2/neu positive tissues.      
Figure 21: 2D immunoblotting of CK19. CK19 was detected after separation of the protein 
across the pH 4-7 at the first dimension. However, isoforms of CK19 with close pI were unable to 
be separated. The separation was then carried out across narrower range, pH 3-5.6. Two of the 
isoforms (yellow circles) were successfully being separated though there was a still a high 
abundant of CK19 remained unseparated. Signal intensity was obtained for the total CK19 
separated with pH 4-7 and the relative expression of total CK19 was calculated. The relative 











4.3.2. Glyoxalase I 
Glyoxalase I (Figure 13; Spot 6) is one of the proteins that are involved in antioxidant and 
detoxification functions. Its differential expression, by some 27-fold, in HER-2/neu-
positive breast tumors, in comparison to HER-2/neu-negative tumor, was clearly evident 
from our proteomics studies. Western blotting analysis, employed to further validate the 
expression, showed higher signal intensity in most of the HER-2/neu-positive cases 
(Figure 23). This was based on the relative calculation of its expression by normalizing 
the Glyoxalase I signal intensity to that of β-actin, where there was about 2.5-fold 
increased expression in HER-2/neu-positive tissues. 
This finding of differential expression of Glyoxalase in the two subtypes of breast cancer 
was also been revealed by the 2D immunoblot (Figure 24). Glyoxalase I on 2D 
immunoblotting showed a 5-fold increased in HER-2/neu-positive samples.  
In addition, the association of Glyoxalase I expression with the HER-2/neu status was 
assessed by the IHC performed on TMA sections. Figure 25 displayed the representative 
weak and strong staining of Glyoxalase I on the TMA. Microscopic examination revealed 
that none of the normal tissues showed any staining for Glyoxalase I (data not shown). 
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Figure 22: Immunohistochemistry analysis of CK19. The expression of CK19 was screened 
with IHC on TMA. The pictures demonstrated the representative cytoplasmic strong and weak 
staining of the CK19 on one of the TMA section (A). Through the statistical analysis (B), 58% of 
the HER-2/neu positive tissues and 19% of the HER-2/neu negative showed strong staining of 
CK19 suggesting strong association of CK19 with HER-2/neu-positivity (p=0.002). [0 - +1: weak 
staining; +2: moderate staining; +3: strong staining] (P-value from Fisher’s exact test) 
B
 However, many of the tumor tissues were effectively stained by the specific Glyoxalase I 
antibody. There were 43% of the HER-2/neu-positive tissues with strong staining of 
Glyoxalase I and only 15% of the HER-2/neu-negative tissues expressed high level of 
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Figure 23: Expression of Glyoxalase I in breast cancer tissues. The expression of glyoxalase in 
HER-2/neu-positive and -negative breast cancer tissues was examined by western blot. 20µg of 
total protein from each case was loaded in for gel running and transferred to PVDF membrane. 
Anti-Glyoxalase I was used for detection and β-actin was detected as loading control. The average 
relative expression demonstrated that 2.5 fold higher expression of glyoxalase I in HER-2/neu-
positive tissues. 
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Figure 24: The expression Glyoxalase I by 2D immunoblotting. Equal amount of pooled 
HER-2/neu-positive and -negative tissue samples were separated by 7cm IPG dry-strip across 
pH 3-10 at first dimension and molecular weight in second dimension. The protein was then 
immunodetected with anti-Glyoxalase I antibody. Signal intensity was obtained and the relative 
expression of Glyoxalase I was calculated by normalizing the intensity of Glyoxalase I in HER-
2/neu-positive to that of -negative. Glyoxalase I in HER-2/neu-positive had shown 5 fold higher 
expressions. 
B 
Figure 25: Statistical analysis of Glyoxalase I analysis. (A). IHC on a TMA was carried out to 
study the expression of Glyoxalase I in larger number of cases. The Glyoxalase was observed to 
be localized in the cytoplasm.  (B). The analysis had found close relation between the 
Glyoxalase I and HER-2/neu status with P=0.023. There was 43% of HER-2/neu-positive cases 
shown strong staining of Glyoxalase I as compared to 15% of HER-2/neu-negative tissues with 
strong staining. [0 - +1: weak staining; +2: moderate staining; +3: strong staining] (P-value 
from Fisher’s exact test) 
 4.3.3. Heat Shock Protein 27 (Hsp27) 
The proteomics results had revealed differential expression of Hsp27 (Figure 13; Spot 4) 
between HER-2/neu-positive and -negative breast cancer. The increased expression of 
Hsp27 in HER-2/neu-positive tissues was confirmed by the Western blot analysis of 7 
additional clinical cases of each of these subtypes. Figure 26 demonstrated a 23kDa band 
was detected in higher intensity in most of the HER-2/neu-positive cases. The average 
relative expression of Hsp27 after normalization with the signal intensity of β-actin was 
about 2-fold enhanced expression of Hsp27 in HER-2/neu-positive tissues, and correlated 
with the proteomics results.  
2D immunoblot studies further validated the differential expression of Hsp27 between 
HER-2/neu-positive and -negative tissues. HER-2/neu-positive samples were shown to 
express about 3 folds more Hsp27 (Figure 27). There was only one spot detectable at the 
area of pH 5 and 23kDa in both the HER-2/neu-positive and -negative tissues (Figure 27).  
The examination using IHC analysis on 87 samples array on the TMA concluded a 
significant association of Hsp27 expression to the HER-2/neu status with P-value 
calculated to be 0.023 (Figure 28). 53% of HER-2/neu-positive cases possessed 
substantial strong staining of Hsp27 at the cytoplasm. On the other hands, there was only 
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Figure 26: Relative expression of Hsp27. The expression of Hsp27 in HER-2/neu-positive and -
negative breast cancer tissues was validated by immunoblotting. 20µg of total protein from each 
case was loaded in analysis. β-actin was detected as loading control. The average relative 
expression of Hsp27 was obtained by normalizing the intensity to that of β-actin. Hsp27 had 
shown to have about 2 fold higher expressions in HER-2/neu-positive tissues. 
 
Figure 27: Validation of Hsp27 level by 2D immunoblot. The proteins samples were separated 
across IPG dry-strip pH 4-7 at the first dimension and subjected to SDS-PAGE at the second 
dimension. Antibody against Hsp27 was added for detection after the transferred of proteins onto 
PVDF membrane. The Hsp27 was detected near its pI of 5 and molecular mass of 23kDa with no 
isoform. The relative expression calculated by normalizing the intensity of HER-2/neu-positive 
to that of -negative indicated higher expression of Hsp27 in HER-2/neu-positive tissues. 
  













4.3.4. Phosphoglycerate Kinase 1 (PGK1) 
PGK1 is one of the enzymes that catalyzes glycolysis pathway which had been identified 
through the analysis of proteome profile at pH 3-10 (Figure 13; Spot 8). It had been found 
to be up-regulated in HER-2/neu-positive breast tissues through the comparative 
proteome profiles of the 2 subtypes of breast tumors. The finding was then supplemented 
by Western blotting analysis by examining more clinical cases. HER-2/neu-positive 
breast tissues had displayed higher relative signal intensities (two-fold elevated) for 
PGK1 (Figure 29).  
Figure 30 shows the detection of 5 spots of PGK1 when the proteins were separated 
across pH 3-10 during the IEF. These 5 isoforms were most probably the various 
phosphorylated forms of PGK1. Most of the phosphorylated form of PGK1 was detected 
at more acidic pH, i.e. Spot 1 is more highly phosphorylation than Spot 2 and so on. 
Evaluation of the intensities of the spots in HER-2/neu-positive samples showed a direct 
correlation to the phosphorylation level of PGK1, where Spot 1 with the highest 
phosphorylation exhibited the highest signal intensity and the intensity was decreasing 
from Spot 2 to Spot 5 (Figure 30).  


















Figure 28: Statistical analysis of Hsp27 analysis. (A). IHC on a TMA was carried out to study the 
expression of Hsp27 in 87 clinical samples. (B). The study had shown considerable association 
between the Hsp27 and HER-2/neu status with P=0.011. There was 53% of HER-2/neu positive 
cases shown strong staining of Hsp27 as compared to 18% of HER-2/neu negative tissues with 
strong staining. [0 - +1: weak staining; +2: moderate staining; +3: strong staining] (P-value from 
Fisher’s exact test) 
 
B 
 The differential expression of PGK1 was further validated by the IHC analysis on the 
TMA (Figure 31). Strong association between HER-2/neu positivity and PGK1 
expression was shown. 43% of the HER-2/neu-positive tissues showed high expression of 
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Figure 29: Validation of PGK1 expression. Western blotting was used for the confirmation of 
PGK1 expression. Equal amount of the proteins from 7 cases of HER-2/neu-positive and -
negative tissues respectively was used for detection of PGK1. A band at around 45kDa was 
detected after the immunoblotting using anti-PGK1. The average intensity of these 45kDa bands 
was calculated and normalized to β-actin band which served as a loading control. The HER-
2/neu-positive tissues had shown increased expression of PGK1 validating our proteomics 
results. 
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Figure 30: 2D Immuno-detection of PGK1. The proteins were separated by 2D electrophoresis 
and blotted onto PVDF membrane for detection of PGK1. There were 5 spots with different 
intensities being detected. These spots were likely to be the phosphorylated PGK1. As PGK1 being 
phosphorylated, it turned to be more acidic thus migrated to lower pH range during the IEF. 
However, this could not be observed with Western blotting as all the spots were having the same 
molecular mass thus being separated as one band. The relative intensity was calculated to be 
increased with the acidity. 
B 
Figure 31: IHC analysis on PGK1. (A) The TMA allowed analysis of PGK1 on 87 clinical 
samples at one go. Most of the HER-2/neu-positive tissues (43%) demonstrated strong staining and 
30% of HER-2/neu-negative tissues showed week staining. (B) Statistical analysis established 
strong association between PGK1 and HER-2/neu status. [0 - +1: weak staining; +2: moderate 
staining; +3: strong staining] (P-value from Fisher’s exact test) 
 
 4.3.5. Fatty Acid Synthase (FASN) 
Comparison of the matched expression proteomes of the two HER-2/neu breast cancer 
subtypes revealed a spot estimated to be 48kDa in HER-2/neu-positive breast tissues to be 
of higher intensity. The protein was identified as FASN (Figure 13; Spot 9). Intriguingly, 
the Western blot analysis detected a band at about 85kDa in addition to the 48kDa band 
(Figure 32). Based on the estimated molecular weight, we proposed that the 48kDa band 
was the Fab B (3-oxoacyl-(acyl-carrier-protein) synthase) fragment and the 85kDa band 
was predicted to be the Fab B and Fab D ((acyl-carrier-protein)-S-malonyl transferase) 
fragment of FASN. The signal intensity from the Western blotting showed a more 
prominent differential expression at the 48kDa band with 7 cases and 2 cases of HER-
2/neu-positive and -negative tissues respectively being observed with this band (Figure 
32). On the other hand, the 85kDa bands had been detected in both HER-2/neu-positive 
and -negative tissues. Nonetheless, the average relative expression for both 48kDa and 
85kDa bands was higher in HER-2/neu-positive tissues (Figure 32). The same trend was 
observed using 2D immunoblotting, where the two spots at 48kDa and 85kDa were 
expressed at a higher level in the HER-2/neu-positive tissues (Figure 33). 
Immunochemical analysis performed on the breast cancer TMA section revealed the 
cytoplasmic staining of FASN with markedly higher expression in HER-2/neu-positive 
tissues (P= 0.002) (Figure 34). 57% of the HER-2/neu-positive tissues showed intense 
staining as compared to only 17% of HER-2/neu-negative tissues.  
Collectively, the results supported the increased expression of FASN in HER-2/neu-
positive tissues. 
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Figure 32: Western blotting analysis of FASN. The analysis revealed two bands estimated at 
85kDa and 48kDa. The 48kDa fragment which was also identified in proteomics studies was 
suggested as Fab B (3-oxoacyl-(acyl-carrier-protein) synthase) fragment and 85kDa band 
correspond to the Fab B and Fab D ((acyl-carrier-protein)-S-malonyl transferase) fragment of 
FASN. The overall average intensity for both fragments verified that FASN was up-regulated in 
HER-2/neu positive tissues. 
Figure 33: Validation of FASN expression. The 2D immunoblotting was performed and FASN 
was detected. In HER-2/neu-positive tissues, there were two spots with different molecular weight 
and pI being detected as compare to that ofHER-2/neu-negative sample where only one spot being 
detected. This finding was consistence with the Western blotting results where most of the HER-
2/neu-positive tissues had shown two bands. However, this 2D immunoblotting demonstrated that 
the bands with lower molecular weight in Western blotting were more acidic. The overall relative 
expression of the FASN was higher in HER-2/neu-positive tissues as shown by the graph.  
  












4.3.6. Raf-1 Kinase Inhibitor Protein (RKIP) 
RKIP (Figure 17; Spot 1) had been identified as one of the protein that showed significant 
differential expression during the study of the alkali proteome profiles (pH 6-9) of HER-
2/neu breast cancer subtypes. This finding had been further validated by Western blotting 
analysis using 7 cases of each subtype. The tumor tissues from the HER-2/neu-negative 
subtype had shown a more intense band at the estimated molecular weight
 
of 25kDa as 
compared to the HER-2/neu-positive tissues (Figure 35). This was especially apparent 
with one of the HER-2/neu-negative tissues (N2). The calculated average relative intensity 
of the RKIP in HER-2/neu-negative breast tissues was about 7-fold higher compared to 
HER-2/neu-positive breast tissues. 
Results from 2D immunoblot showed that RKIP expression in HER-2/neu-negative 
tissues was about 4-fold higher than HER-2/neu-positive tissues (Figure 36).  
 



















Figure 34: Immunochemistry on FASN. The TMA array consisting of the tumor and the matched 
normal breast tissues were analyzed for FASN expression using IHC. The studies suggested strong 
correlation of FASN to the HER-2/neu-positive with P value determined to be 0.002. This was 
supported with 57% of HER-2/neu-positive tissues showing strong FASN staining. 
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Figure 36: 2D Immunoblot detection of RKIP. The respective proteins from HER-2/neu-positive 
and -negative tissues were separated by 2DE. The RKIP was detected using monoclonal antibody. 
The intensity of the spot was determined and HER-2/neu-negative tissues had shown 4 fold 
increased in RKIP expression. 
Figure 35: The average relative expression of RKIP. Western blotting was performed using 
more cases of tumor tissues. The RKIP was detected with its corresponding monoclonal antibody. 
Most of the cases of HER-2/neu-negative tissues especially N2 had expressed higher amount of the 
RKIP with higher intensity of the bands being detected. The average relative expression of the 
RKIP was obtained after normalization the signals to that of β-actin. The HER-2/neu-negative 
tissues generally had about 7 fold increased in RKIP expression. 
 4.3.7. Bip/GRP78 
Bip/GRP78 (Figure 15; Spot 2) showed a similar expression trend to that of RKIP. It was 
also identified to be overexpressed in HER-2/neu-negative breast tissues in the 2DE gel 
images examination. Western blotting had been carried out as a confirmatory test of the 
studies detecting a band at around 75kDa. HER-2/neu-negative tissues was determined to 
have differentially elevated level of Bip/GRP78 based on the relative signal intensities 
calculated supporting our observations on 2D profile matching (Figure 37). 
In another validation test through 2D immunoblotting (Figure 38), there was a single spot 
detected at around pH 5, with a molecular weight of 75kDa. The relative expression 
calculated based on the spot intensity had also confirmed our proteomics observations 
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Figure 37: Confirmation of Bip/GRP78 expression. The expression of Bip/GRP78 obtained 
from 2DE was checked against Western blotting. Equal amount of protein from every case was 
loaded for SDS-PAGE and transferred to PVDF membrane for immuno-detection. The relative 
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4.3.8. Heterogeneous nuclear ribonucleoprotein H1 (hnRNPH1) 
The analysis of acidic proteome profiles of the matched HER-2/neu breast cancer 
subtypes had revealed the up-regulation of hnRNPH1 (Figure 15; Spot 15) in HER-2/neu-
positive breast tissues. This positive association of hnRNPH1 and HER-2/neu was 
checked against Western blotting. The signal intensity was consistently observed to be 
more intense in HER-2/neu-positive breast tissues (Figure 39). However, the detected 
band had a molecular weight of around 35kDa which had been proposed to be the 
posttranslational cleavage product of the 57kDa full length hnRNPH1 protein, from a 
study on cell lines transfected with hnRNPH1 [68]. This was consistent with our 2D 
results, where the molecular weight of the spot recognized to be hnRNPH1 was also 
estimated to be 35kDa. There was no visible band detected at 57kDa but we cannot 
exclude the existence of such a band as there might be very low level of full length 57kDa 
hnRNPH1, which could not be observed with 20µg of total proteins. Nonetheless, the 
average relative expression of 35kDa hnRNPH1 was shown to be 4-fold higher in HER-
2/neu-positive cases, thus confirming the proteomics observation.   The results were 
further validated by 2D immunoblot. There were 3 and 2 spots of similar molecular 
weights, but of different pIs detected in HER-2/neu-positive and -negative breast tissues, 
Figure 38: Determination of Bip/GRP78 expression. The relative expression of Bip/GRP78 was 
determined through 2D immunoblot. The Bip/GRP78 was detected using monoclonal antibody 
against Bip/GRP78 and the signal intensity was obtained. The relative intensity calculated had 
shown that there was higher expression of Bip/GRP78 in HER-2/neu-negative tissues.  
 respectively (Figure 40). These findings support the earlier-mentioned indications of 
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Figure 40: 2D immunoblotting detection of hnRNPH1. The 2D immunoblotting had revealed 
the multiple isoforms or phosphorylation of the hnRNPH1. Spot 1 was the hnRNPH1 that has not 
underwent any modification. Spot 2 and 3 were most likely to be the phosphorylated form of 
hnRNPH1 that had migrated to more acidic end during the IEF. These 2D immunoblotting 
demonstrated not only the increased expression of hnRNPH1 in HER-2/neu-positive tissues but 
also the phosphorylation level. 
Figure 39: Western blot analysis of hnRNPH1 expression. 20µg of samples was loaded for the 
analysis. The bands detected were determined to be 35kDa with no visible band of 57kDa full 
length hnRNPH1. Nonetheless, the calculated relative intensity showed the same trend as 
proteomics profile, where hnRNPH1 expression was higher in HER-2/neu-positive tissues. 
 5. Discussion: 
5.1. The Importance of the Materials Used and Techniques Employed 
HER-2/neu amplification/overexpression in breast cancer has been consistently related 
with more aggressive phenotypes and increased possibility of tumor progression as well 
as metastasis. Identification of the differentially regulated proteins and the biochemical 
endpoints in HER-2/neu overexpressed breast cancer tumors is thus essential in 
understanding the underlying molecular mechanisms leading to the aggressiveness.  
Breast cancer tissues has been chosen for this study as there is growing recognition that 
mammary stroma cells play an important role in tumorigenesis [69]. The findings based 
on dissected breast cancer tissues containing tumor cells aroused following the crosstalk 
between the malignant epitheliums and the surrounding stromas may be more appropriate 
in studying the molecular events. This is opposed to breast cancer cell lines consisting of 
homogeneous cancerous cells which are grown and maintained in monolayer without 
stroma cells interactions. Furthermore, breast cancer cell lines are derived from divergent 
tumors representing different stages of disease and may lack the biological relevance 
reflecting the true molecular events occurring during tumorigenesis [65, 70].  
Recent advance in proteomics strategies with the ability to resolve the whole proteome 
including the post-translational modifications (PTMs) and to identify many proteins of 
interest [71] concurrently had been employed for this study. Comparative gel-based 
proteomics or 2DE have been performed on HER-2/neu-positive and -negative breast 
cancer tumors to obtain a snap-shot of the whole proteomes. LCM has been used in 
refining the pure and homogeneous population of tumor cells for the analysis of the 
proteome separated by the wide range IPG (pH3-10). This eliminated the 
misinterpretation of the data due to the presence of a mixture of normal and tumor cells 
within a sample. The results reflected only the changes of protein expression in tumor 
cells without the possibility of contamination from the normal cells. 
 Precautionary steps had been taken when performing LCM. During the paraffin 
infiltration procedure, it is important to avoid formalin fixation because formalin induces 
extensive protein cross-linking [72]. This reduces the quantity and the quality of the 
protein recovery for high-throughput expression studies such as 2DE. Thus, in our 
project, we had performed ethanol-fixation which was reported to be useful in the 
evaluation of molecular profiling studies [73]. 
During the Hematoxylin staining of the sections, we had reduced the standard 
concentration of this dye to 10%. This allowed clear differentiation of breast tumor cells 
from other cell types and eased the procurement of the tumor cells by LCM. With this 
modification, the recovery of the proteins was also improved. In addition, we had 
consulted the pathologists in our department to assist in the identification of the desired 
cell types for LCM to ensure pure population of the breast tumor cells being procured. 
When performing the hematoxylin staining, protease inhibitors should be added into all 
the solutions except xylene according to the manufacturer’s instruction, at the optimal 
working concentration to minimize protein degradation. The staining was also performed 
as closed as possible to the scheduled LCM dissection. 
During the microdissection, precautions were taken to ensure no irregularities on the 
tissue surface in or near the area to be microdissected. This allows maximum contact of 
the LCM cap to the tissue surface for tight adherence of the dissected cells to the cap 
during laser activation.  
Although the broad range pH gradient (pH 3-10) separation of LCM dissected proteins 
had allowed unambiguous identification of some of the HER-2/neu-associated proteins, it 
was insufficient to resolve the complete proteome. It could reveal only a small percentage 
of the whole proteome as there is enormous diversity of proteins due to extensive co-
translational modifications and PTMs of proteins as well as differential gene splicing. 
Multiple narrow overlapping IPGs (pH4-7 and pH6-9) had thus been employed to achieve 
 an optimal resolution and to avoid numerous proteins superimposed on one another at a 
single spot. This also facilitated the application of larger amounts of  proteins to aid the 
detection of minor components and low abundance proteins [71]. 
During the separation of alkali proteins across pH6-9, anionic cup loading had been 
employed. This is because basic proteins have difficulty entering the IPG dry-strip when 
applied through in-gel rehydration [74], due to the hydrophobic interactions between the 
proteins and the wall of the tray. In addition, HED had been added into the rehydration 
buffer replacing the DTT during the separation of the alkali proteomes. DTT could be 
ionized at basic pH and run short in the alkaline gel area due to its migration to the anode 
during IEF. The depletion of the DTT eliminates the reducing condition which is 
essentially for sharp focusing of the proteins during IEF and thus causing streaking effect 
on the 2D images [74]. With the used of HED, the cysteines can be stabilized as mixed 
disulfides [74] to avoid streaking effects besides improving the reproducibility [74]. 
Optimum focusing time is very important to obtain high quality and reproducible 2D 
profiles. Too short focusing time will result in horizontal streaking but severe over-
focusing should also be avoided. The optimum time must be determined empirically for 
each combination of protein sample, protein loading and the particular pH range and the 
length of the IPG dry-strip [74]. Longer time is usually needed for the optimal focusing of 
the alkali proteins. The best focusing voltage and time for the separation of the proteins 
across pH6-9 were determined to be 8000 V for 6hr 53min (55kVhr) as compared to 6hr 
(48kVhr) and 5hr (40kVhr) at 8000V for separation of proteins across pH3-10 and pH4-7 
respectively. 
The reproducibility of 2DE is always a questionable issue due to the complexity of the 
process involved in these techniques. 2DE is a multistep procedure. Inconsistencies in 
each of the step can affect the reproducibility of the results obtained. Each of the steps, 
beginning from the sample preparation to the staining of the 2D profiles, had been kept as 
 consistent as possible to ensure a good reproducibility. A single extraction was performed 
to obtain sufficient amount of the proteins for at least three replicates of 2DE. The 
extracted proteins were aliquoted separately into different microfuge tubes at certain 
amount and stored at -80°C until further use.  This is important especially for the proteins 
extracted from the fresh frozen breast cancer tissues, as there was additional step of 
acetone precipitation performed for the salt removal. Salt increases the conductivity of the 
IEF, thereby prolonging the time required to reach the steady-state, as such it needs to be 
removed.   
Commercially available ready-made IPG dry-strips were used in the separation during 
IEF. These ready-made IPG dry-strips contained extremely stable pH gradient across the 
strip thus increasing the reproducibility. Besides, the strips are easier to handle and could 
provide better comparability of results and exchange of data. 
The silver staining step is also critical to ensure the reproducibility. Each of the optimized 
steps in the silver staining procedures had been adhered strictly. It is very important to 
incubate the gels according to the pre-determined optimal time. During the developing 
steps, the gels were also consistently and carefully being observed for the desired 
intensities. 
Computer software had been used in our image analysis. The software, which is capable 
of background correction and normalization of the spot intensities, minimizes the 
interpretation errors due to gel-to-gel variations. The detection, matching and 
quantification of the spots could be performed relatively quickly by the software and does 
not require much user interactions. However, the software does not always identify all 
spots correctly especially with areas that have many or overlapping spots. Hence, manual 
spot editing with reference to the original stained 2D gels were always performed before 
proceeding to the gel matching step. The gel-matching step is when each spot on the gel 
is matched to its counterpart on the other gels. Landmark spots must be identified 
 manually to allow the software to proceed with the gel-matching. The selected landmark 
spots were ensured to be evenly distributed across the entire gel area to allow accurate 
matching of the gels. Again, mismatching was checked and edited manually. Manual 
comparison of the spot intensities on the original gels was also performed before the 
differentially expressed proteins identified by the software were selected for MS analysis.  
In-gel digestion was performed with extra care to avoid keratin contamination that will 
interfere with the protein identification during the MS analysis. Only doubled-distilled 
water (Mili-Q) was used for the washing of the gel pieces and the preparation of the 
reagents required for the in-gel digestion. The in-gel digestion was performed in a clean 
and isolated environment. The regular changing of gloves as well as wearing a mask were 
precautionary measures taken to reduce the contamination. The optimal concentration of 
trypsin for complete peptides digestion had been determined to be 40ng/ml and the 
incubation had to be done overnight at 37°C to allow complete digestion of the peptides. 
To obtain a very reliable set of the proteomics results, three replicates were performed for 
each pooled sample from HER-2/neu-positive and -negative respectively. Only those 
spots showing significant differential expression in at least 2 replicates were excised for 
further analysis. To further confirmed the results of the differential expression obtained 
from the 2DE, further validation of the expression of eight of the identified proteins 
(CK19, PGK1, FASN, Glyoxalase 1, Hsp27, RKIP, Bip/GRP78 and hnRNPH1) through 
immunoblotting was performed. Literature review on previous studies for the expression 
of the identified proteins in breast cancer and other cancer types had also been performed 
to further confirm the results.  
There were only 8 proteins being selected for the confirmatory studies because it is very 
time-consuming and expensive to study all of the identified proteins. The proteins were 
selected based on their biological functions. In-depth studies for their roles in tumor 
progression and the association with HER-2/neu status will be the future interest. 
 However, the selection was also subjected to the availability of the antibody against the 
protein of interest.  
With these precautionary steps taken into account for the technical deficiencies, reliable 
proteomics results had been ensured for unraveling the possible molecular mechanisms 
associated with HER-2/neu overexpressed breast tumors. 
 
5.2. The Significance of the Proteomics Results 
Our data had shown the feasibility of high resolution narrow overlapping pH gradient in 
combination with wide range pH gradient during the gel-based proteomics approach to 
generate protein expression profiles and to identify potential candidates participating in 
the molecular events associated with HER-2/neu-positive breast tumors. Although the 
differential expression screening through the proteomics techniques does not provide 
direct evidence that a given protein plays a critical role in the phenotypic changes 
associated with HER-2/neu overexpression, a review on the literatures for their functional 
studies indicated that they may be candidates. This restricted the potential candidates and 
pointed an appropriate direction for the further studies of the disease. Subsequent 
evaluations on these potential candidates might provide alternative therapeutic target for 
the HER-2/neu-mediated breast cancer. 
Based on the results, we propose that there are diverse pathways involved in the 
molecular mechanisms of HER-2/neu-mediated tumorigenesis. These pathways may be 
interlinked as part of the signal transduction cascades initiated either by spontaneous 
HER-2/neu activation due to overexpression or excessive receptor stimulation after ligand 
binding (Figure 41).  
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Figure 41: Postulated molecular signalings of HER-2/neu overexpressing breast cancer. There are multiple pathways involving in the HER-2/neu-
promoted tumorigenesis. These pathways may act by itself or in concert with other signaling cascades to inhibit apoptosis but induce cell proliferation 
and metastasis. In consequence, highly aggressive and metastatic phenotypes of breast cancer are presented. 
 
 
 5.2.1. Intermediary Metabolism 
5.2.1.1. Glycolysis 
The HER-2/neu activities could stimulate the intermediary pathways such as glycolysis 
and fatty acid synthesis through elevated levels of enzymes involving in these processes. 
These augmented functions and proteins level are essential in providing adequate energy 
in rapidly proliferating tumor cells. Metabolic changes during malignant transformation 
have been noted for many years. Since the discovery of high levels of anaerobic 
metabolism in cancer cells despite sufficient oxygen supply, a high level of carbon flux 
through glycolysis has become a hallmark of the transformed phenotype, occurring most 
commonly in rapidly proliferating tumors [75].  Even as far as 1987, there were already 
studies demonstrating increased activity of glycolytic enzymes (hexokinase, 
phosphofructokinase, aldolase, enolase and pyruvate kinase) in breast cancer tissues [76] 
as well as breast cancer metastases occurring at various sites [77].  
PGK1 is one of the glycolytic enzymes demonstrated to be overexpressed in pancreatic 
ductal adenocarcinoma (PDAC) tissues [78] and, elevated levels of PGK1 were detected 
in serum samples of the PDAC patients [78]. Besides its role in glycolysis, PGK1 may be 
secreted by the tumor cells and may also participate in the angiogenesis process as a 
disulfide reductase [79], which led to it being considered as an appropriate target 
molecule for specific immunotherapy of HLA-A2+ colon cancer patients. These findings 
on PGK1 have substantiated the proposal that PGK1 is a potential candidate associated 
with the more aggressive type of HER-2/neu-related breast cancer.  In this study, these 
correlations were validated by Western blot and IHC. Post-translational modifications of 
PGK1 had been demonstrated with 2D immunoblots but this modification was not 
observed in the silver-stained proteome profiles. This may be attributed to adherence to 
the inclusion criterion that only spot with more than two-fold changes in intensity in 2D 
profiles would be further analyzed which may thus exclude spots such as those of PGK1 
 isoforms with lower differentials. Furthermore, post-translationally modified proteins 
such as phosphorylated proteins can give quantitatively and qualitatively different 
staining intensities when compared to similar amounts of other non-modified proteins 
[74]. Association of various isoforms of PGK1 with HER-2/neu status therefore can not 
be excluded and confirmation of this requires further investigations. The results are 
supportive on the involvement of glycolytic enzymes in HER-2/neu-linked breast cancer 
but, the mechanisms by which HER-2/neu signaling regulates expression of these 
enzymes have yet to be better defined. 
 
5.2.1.2. Fatty Acid Synthesis 
In addition to the striking changes in glucose metabolism in human cancer, lipid 
metabolism was also shown to be altered during the course of tumorigenesis. De novo 
fatty acid biosynthesis is an anabolic energy-storage pathway largely considered of minor 
importance in humans as in normal circumstances, dietary lipids would provide the fatty 
acids needed for growth.  However, reports of overexpression and hyperactivity of FASN, 
a key enzyme of de novo fatty acid synthesis, in many cancer cells [80] such as those of 
the prostate [81], and the breast [82], and in this study have led to changing perspectives 
on the role of lipogenesis in cancer biology.  Several recent studies had shown that almost 
all of the fatty acids in the tumor cells are derived from de novo synthesis despite 
adequate nutritional supply [81]. FASN overexpressing tumors had also displayed a more 
aggressive biological behavior [81]. Our works have presented additional support for this 
claim by showing that the more detrimental HER-2/neu-positive breast cancers expressed 
FASN to higher levels. Together with the data from a cDNA microarray analysis on 
breast cancer cell lines [35], and the detection of elevated fatty acid synthase protein 
expression in HER-2/neu overexpressing breast cancer cell lines [80], the confirmatory 
 results using immunoblotting and immunohistochemistry (P=0.002) as validation tools, 
had strongly corroborated the association of HER-2/neu overexpression with FASN. 
The bi-directional nature of the molecular connection between HER-2/neu and FASN-
dependent neoplastic lipogenesis has been recognized as well. HER-2/neu may act as an 
upstream regulatory factor that stimulates the FASN gene promoter [35, 80] and increase 
fatty acid synthase translation specifically through the PI3K pathway [35], whilst, 
pharmacological inhibition of FASN activity in turn negatively regulates the expression 
and tyrosine kinase activity of HER-2/neu [80]. The inhibition also synergistically 
induced cytotoxicity on the Herceptin-treated HER-2/neu overexpressing breast cancer 
cell lines [83]. These results and our findings pointed towards a promising therapeutic 
approach against HER-2/neu overexpressed breast carcinoma through combinations of 
FASN and Herceptin. 
 
5.2.2. Cellular Defense 
Besides providing the energy for the cell growth, these intermediary metabolisms of 
glycolysis and lipogenesis, also produced by-products or reactive oxygen species (ROS) 
such as superoxide anion (O2.-) and hydrogen peroxide (H2O2). These ROS cause 
detrimental damages to many of the cellular components for instance DNA, proteins and 
lipids. For their survival, cells have developed different reparative systems to combat the 
toxic process of ROS. These cytotoxicity effects can be counteracted with the initiation of 
the detoxification processes, in line with our findings of more than 10% of the identified 
proteins were involved in cellular ROS defensive systems. This also suggested a crosstalk 
between the cellular defenses with the intermediary metabolisms through HER-2/neu 
mediated signaling. 
We had demonstrated increased expression of GLO I in HER-2/neu-positive tissues and 
further validated these findings with western blotting and IHC on a TMA section. The 
 strong correlation (p = 0.023) between the HER-2/neu status and GLO I expression is not 
unexpected as GLO I is the enzyme that irreversibly converts methylglyoxal (MG) to D-
lactic acid and it was found to be up-regulated in many cancers including breast [84] and 
lung [85]. MG is a toxic by-product produced by the triose-phosphate intermediate in 
glycolysis. It has high reactivity in glycation reactions using DNA, proteins or lipids [86] 
as substrates and accumulation of MG lead to cell death. The proteomics results in this 
study had also demonstrated increased expression of triose-phosphate isomerase (TPI) in 
HER-2/neu-positive breast tumors, which is responsible for the catalysis of triose-
phosphate isomerase during glycolysis. Thus, increased GLO I expression might be the 
consequence of increased expression of TPI and elevated glycolysis in the HER-2/neu-
positive tissues, where it may play a vital role in removing MG and ensuring survival of 
the cells. Due to its ability to protect cells from MG-mediated apoptosis, GLO I has been 
prompted as a potential therapeutic target, with the desired anti-tumor activity achieved 
by inhibiting GLO I activities [87]. Our study firmly established the link between the 
HER-2/neu overexpressed breast cancers and GLO I, offering another alternative of 
therapeutic intervention in the treatment of this breast cancer subtype. 
 
5.2.3. Signaling Pathway Inhibition 
To maintain normal homeostasis, the cells are always equipped with negative feedback 
systems to avoid excessive stimulation of a pathway as demonstrated by the signaling 
pathway inhibitory proteins such as RKIP. In our studies, RKIP had been unambiguously 
identified to be down- regulated in HER-2/neu-positive breast cancer and the 
confirmation on differential expression of RKIP was supplemented with immunoblotting. 
RKIP plays a pivotal modulatory role in several protein kinase signaling cascades 
especially MAPK signaling [88]. RKIP had been demonstrated to bind to either Raf-1 or 
MEK and prevent the phosphorylation of the down-stream signaling molecules of Raf-1 
 and MEK thus the MAPK signaling is diminished [89]. On the other hand, 
phosphorylation of RKIP by the PKC alleviated its inhibitory effect on Raf-1 [90]. 
Nonetheless, there was no observation on phosphorylated isoforms of RKIP during the 
analysis of the 2D immunoblot. This speculated the inhibition of RKIP phosphorylation 
by HER-2/neu to safeguard the RKIP in its non-phosphorylated form for its inhibitory 
effect, or the level of phosphorylation was too low to be detected. RKIP was identified to 
be differentially expressed based on the pooled samples of the HER-2/neu-positive 
and –negative respectively after the 2DE analysis. In Figure 35, the individual tumors 
had been tested for the RKIP expression by Western blot. The high error bars might 
be due to the case-to-case variation but overall the differential expression of RKIP 
was still significant between HER-2/neu-positive and –negative breast tumors. 
Aberrant RKIP expression plays a critical role in cancer by functioning as a metastasis 
suppressor. Its expression had been shown to be reduced in both metastatic prostate 
cancer cell lines as well as tissues [88]. Furthermore, RKIP restoration in metastatic 
prostate cancer cells reduced spontaneous lung metastasis. However, RKIP restoration did 
not retard primary tumor growth rate implicating RKIP suppresses metastasis without 
affecting the tumorigenecity [91]. This was further supported with the negative 
correlation of RKIP expression with breast cancer metastasis [92]. Excessive MAPK 
cascades activation due to HER-2/neu overexpression might explain the higher metastasis 
rate occurring within this tumor subtype. With the reduction of RKIP in the HER-2/neu-
positive tumors, inhibitory effect on the MAPK cascade has been minimized thus 
presenting an additional beneficially factor in assisting the metastasis of this breast 
cancer.  
 
 5.2.4. RNA Processing 
With the HER-2/neu-mediated suppression of RKIP, there could be uncontrolled MAPK 
and PKC signaling pathways activation and induction of oncogenic transcription factors 
which in turn would amplify the expression level of hnRNPH1. Heterogeneous nuclear 
ribonuclear proteins (hnRNP) are abundant nucleoplasmic pre-mRNA-binding proteins 
which have important roles in the biogenesis of mRNA [93]. To date, a total of 19 genes 
have been identified and some of the isoforms were derived from the alternate splicing of 
the same gene [94]. Many hnRNP (A1, A2, D, F, H, H’, and K) had been shown to 
contain upstream binding elements for oncogenes such as E2F, AP1 and c-myc at its 
promoter region [94]. The presence of these binding elements in the promoter region may 
cause increased expression of hnRNP during malignancy. Our results had identified a 
member of this family, hnRNPH1, to be overexpressed in HER-2/neu-positive breast 
tumor tissues. This observed differential expression of hnRNPH1 had then been further 
validated through immunoblotting. hnRNPH1 is part of the nuclear matrix protein taking 
part in stimulating pre-mRNA cleavage and polyadenylation [95]. hnRNPH1 is also a 
component of a splicing enhancer and participates in pre-mRNA splicing [95]. In 
addition, hnRNPH had been reported to be overexpressed in many cancers including skin, 
lung and liver [95], and its main subcellular localization was in nucleus. The increased 
level of hnRNPH1 in HER-2/neu overexpressed tumors and other cancers is likely to 
account for elevated transcriptional and translational activities in these rapidly 
proliferating tumors. 
Post-translational cleavage of the hnRNPH1 had also being reported in a fibroblast cell 
line transfected with hnRNPH1 [68]. The transfected cells produced a variant at 35kDa 
[68] in addition to the full length 57kDa proteins. Interestingly, only the 35kDa band had 
been observed in our immunoblotting suggesting an important role of this 35kDa in the 
development of the HER-2/neu-positive breast cancer subtype. The cleaved 35kDa 
 hnRNPH1 is expected to present an added function which is not encoded by the full 
length protein. This had been accounted for in another member of the family, hnRNPA1. 
In hnRNPA1, there was proteolytic cleavage to produce a UP 1 fragment which 
stimulates activity of DNA polymerase α, an activity which is not found in hnRNPA1 
protein itself [96]. The 35kDa hnRNPH1 that had been detected in the tumor samples in 
this study might resemble the UP 1 fragment and interacting synergistically with HER-
2/neu to promote the tumorigenesis. The functional significance of this differential 
expression as well as the synthesis of the proteolytic cleavage fragment in relation to 
HER-2/neu overexpression, however, needs to be further evaluated. 
 
5.2.5. Molecular Chaperones 
Molecular chaperones are essential for protein folding, translocation across cellular 
compartments, assembly and maintenance of multiprotein complexes in activation- 
competent states. The chaperones also prevent self association of multimeric proteins and 
direct misfolded and short-lived proteins to destruction by the proteosome [97]. When a 
cell returns to the normal state after experiencing physiological and environmental insults, 
the damaged proteins could be either refold to their native forms or are transferred to the 
degradative machinery through the interaction with molecular chaperones [97]. The 
cellular chaperones comprise a large and heterogeneous group. Heat-shock protein (HSP) 
and glucose regulated protein (GRP) are such two chaperones that are induced by a wide 
variety of different physical, chemical and biological stimuli [98]. Hsp27 has been 
implicated to be overexpressed in breast invasive ductal carcinoma and cell lines [55, 99] 
as well as other cancers [100, 101]. Our proteomics results where Hsp27 was found to be 
overexpressed in HER-2/neu positive breast tumor tissues and further validations by 
immunoblotting and IHC, fall inline with these earlier supports. The main cellular 
functions of Hsp27 are related to actin dynamics and prevent apoptosis through 
 mechanism involving specific interaction with cytochrome c.Apaf-1.dATP complexes in 
procaspase 9 pathways [102]. Stable Hsp27 is a dimer but it can oligomerize to form 
tetramers or oligomers [101].  Phosphorylation of specific sites on the Hsp27 
macromolecule, on the other hand, is responsible for the partial dissociation of oligomers 
and the interaction with a distinct target protein involved in apoptosis as was reported in 
renal cell carcinoma [101]. Based on the 2-D immunoblot of the tumors in this study, 
there was no any other isoforms being observed due to the PTM [101]. This is probably 
due to the prior sample treatment which may cause dephosphorylation of Hsp27 or the 
expression level of other isoforms may be too low to be detected.  
Increased expression of chaperones was found in many neoplastic cells such as breast, 
renal and osteosarcoma [97] when compared to their normal counterparts. Interestingly, 
three chaperones (GRP78, Hsp70, and calrecticulin) had been identified to be down-
regulated in HER-2/neu-positive breast tumor tissues. This decreased expression of 
GRP78 had been further validated using more cases of clinical samples through 
immunoblotting where GRP78 had been indisputably shown to be negatively correlated 
to the HER-2/neu. A study on GRP protein expression in human breast cancer cell lines 
had revealed increased expression of GRP78 in the HER-2/neu negative cell lines as 
opposed to the HER-2/neu positive cell line [103]. In the same study, the expression of 
GRP78 was shown to be stimulated after the treatment of cells with two endoplasmic 
reticulum (ER) stress inducing agents, tunicamycin and tharpsigargin [103]. This 
phenomenon was further supported by the decreased protein and mRNA expression of 
GRP78 in HepG2 cells overexpressing an oxidative stress agent (CYP2E1). In this cell, 
the induction of GRP78 expression after tharpsigargin addition to the cells was also 
observed [104]. Hsp70 is a chaperone closely related to GRP78. Our results had shown 
down-regulation of Hsp70 in HER-2/neu-positive breast tissues. A HER-2/neu transfected 
cell line had also demonstrated decreased expression of Hsp70 [105]. These observations 
 supported the functional role of HER-2/neu in suppressing the expression of GRP or other 
functionally related chaperones. This suppression however is likely to be disseminated 
after the cells have been aggravated with unfavorable insults such as ER stress. The HER-
2/neu-positive tissues that have been examined in our project might not have suffered 
from such insults resulting in suppression of these chaperones. 
Thus, Hsp27 and GRP78 are needed in maintaining the proteins in the native 
conformations to avoid cell death due to aggregation of the damaged proteins. 
 
5.2.6. Structural Reorganization 
We also speculate that HER-2/neu activation could lead to changes in the expression level 
of cytoskeletal proteins for instance CK19 and tropomyosin to allow structural 
reorganization and cell dissemination to various parts of the bodies.  
CK19 had been identified as one of the structural proteins to be associated with HER-
2/neu-positive breast tumors through the proteomics studies. Further confirmation of 
CK19 differential expression through IHC had shown a strong correlation of CK19 to 
HER-2/neu (p = 0.002). Since the specific isoform(s) of CK19 could not be separated 
even with the narrower pH range and real-time PCR was not performed to study for 
the expression of the specific isoforms, thus the conclusion was drawn based on the 
expression of the total CK19. Our result from the Western Blot and IHC clearly 
demonstrated the differentially expression of total CK19 and this firmly established 
the association of total CK19 expression with HER-2/neu overexpression. However, 
the identification of specific isoforms of CK19 through real-time PCR should have 
been done to have a better understanding of the association between CK19 and HER-
2/neu. 
CK19 is an intermediate filament that is present in relatively high abundance, which is 
involved in organizing the structure of normal epithelium. Its expression is often altered 
 in breast [7, 105, 106] and other cancers [106]. A significantly higher incidence of early 
tumor recurrence and extrahepatic disease was found in patients with CK19 positive 
hepatocarcinoma (HCC) than in those with CK19-negative HCC. This was attributed to 
increased metastasis of CK19 expressing HCC. Serum levels of CYFRA 21-1, a CK19 
fragment, have been used as a tumor marker in a variety of cancers, such as non-small 
cell lung cancer [107], breast cancer [108-110], ovarian cancer [111], and liver cancer 
[112] with the aim of detecting occurrence of metastasis and tumor cell dissemination. A 
recent study had also detected increased CK19 mRNA level in the peripheral blood of 
HER-2/neu overexpressing breast cancer patients [113]. These observations are consistent 
with our findings and are of interest given the fact that HER-2/neu overexpression is 
associated with increased metastatic potential. Evidence of CK19 enhancement was 
proposed as a predictive diagnostic biomarker and/or a prognostic factor for reduced 
disease-free interval and overall survival, respectively [113]. Their potential can be 
further tested in a larger study with clinical biopsy materials. 
Tropomyosins are integral components of the microfilament cytoskeleton where they bind 
actin filaments and stabilize their structure.  Its biological function in non muscle cells 
however is not clear. Tropomyosin 1 and 3 have been reported to be down-regulated in 
breast cancer [114] but up-regulation had been described in other cancers [115-117]. It 
had also been shown to induce lamellipodial formation, increase cellular mobility and 
reduce stress fibers [118] all of which are necessary for acquisition of the metastatic 
phenotype in tumor cells. Metastasis-mediated proteome study of highly metastatic breast 
cancer cell line [119] as well as matching of poorly metastatic and highly metastatic 
sublines of a lung giant cell lung carcinoma cell line have demonstrated the 
overexpression of tropomyosins in highly metastatic cells [120]. In this study, the 
enhanced expression of two isoforms of tropomyosin (tropomyosin 3 and tropomyosin 1 
 (α)) in HER-2/neu overexpressed breast tumors may present an added function of 
tropomyosins in this breast cancer subtype to facilitate metastasis. 
 
5.2.7. Protein Catabolism 
Cathepsin D is the only protein involved in protein catabolism and tissue remodeling that 
had been identified by our proteomics results. Cathepsin D overexpression plays an 
imperative role in the multiple steps of tumor progression, in stimulating cancer cell 
proliferation, fibroblast outgrowth, angiogenesis, as well as tumor apoptosis [121]. An 
elevated level of this enzyme had been noticed not only among the patients with breast 
cancer but also among those with other solid tumors. It is also frequently correlated with 
poor prognosis, high risk of relapse and metastasis and shorten survival period [122]. 
These findings and critical role of cathepsin D in promoting tumor development have 
firmly supported our results where cathepsin D was identified to be overexpressed in the 
more aggressive form of HER-2/neu-positive tumors. Though the mechanisms by which 
the overexpression of cathepsin D contributes to tumor relapse and metastasis are not 
fully understood, it had been suggested to either activate the growth factor pathways or 
inactivate growth inhibitors [122]. It could also be secreted from the tumor cells to 
function as an autocrine mitogen where it interacts with different membrane receptors to 
facilitate cell growth. Thus, we propose that the growth promoting signaling cascades in 
HER-2/neu-positive tissues could be synergistically stimulated with the interaction of 
HER-2/neu and secreted cathepsin D as well as direct activation of high abundant 
cathepsin D in the cells. However, this conjecture needs further evaluations.  
 
5.2.8. Transportation and Adaptation  
Transporter or adaptor proteins comprised 24% (9 of 35) of the identified proteins in our 
comparative proteomics results. These proteins are likely to be expressed in high 
 abundance within cells; as such they had been easily identified by the proteomics 
approach. The association of these proteins with the HER-2/neu overexpressing breast 
tumors certainly implies a functional role in the HER-2/neu-mediated tumorigenesis.    
Galectin-1 had been identified to be down-regulated in HER-2/neu-positive tissues 
through the proteomics studies. The expression of galectin-1 had been well documented 
in many different tumor types [123]. However, conflicting results had been published, 
resulting in discrepancies in drawing a clear picture of galectin-1 expression profiles in 
cancers. Heterogeneous expression of galectin-1 was reported in a series of colon 
carcinoma samples, without modulation between normal and tumor cells. Increased 
expression of galectin-1 had been shown in cancer cells of the bladder and the thyroid 
[123] while decreased expression of galectin-1 was detected in head and neck cancers 
[123]. This inconsistency of galectin-1 expression could be attributed to the multiple roles 
of galectin-1 in association with cancer biology. Galectin-1 may play a key role in the 
initiation of transformed phenotype of tumors by interacting and activating the oncogenic 
H-RAS for cell transformation [124]. Galectin-1 could also function as a growth 
promoting factor as demonstrated when the inhibition of gal-1 gene expression in a rat 
glioma cell line arrested tumor growth.  In addition, modulation of cell growth by 
galectin-1 may also be biphasic with high doses of galectin-1 inhibiting cell proliferation 
while low doses were mitogenic. Galectin-1 is also a binding protein associated with cell 
cycle regulation, apoptosis, cell adhesion, migration and inflammation [124]. Since 
galectin-1 is involved in diverse functions, in-depth studies should be done to draw better 
picture of relation between HER-2/neu and galectin-1 in breast cancer biology. 
Annexin A2 is another adaptor protein that had been identified. Annexins are a family of 
calcium-dependent, phospholipids-binding proteins with more than 20 different isoforms 
being identified [125]. The expression of annexin A2 had been reported to be reduced or 
lost in prostate cancer [126] and osteosarcoma [127], which is consistent with our results 
 where we found that there was an inverse correlation of annexin A2 expression to HER-
2/neu overexpression. While the precise function of annexin A2 is unclear, it had been 
shown to be involved in Ca2+-dependent exocytosis, endocytosis and cell adhesion [128]. 
In addition, annexin A2 had also been proposed to be linked to tumorigenesis where its 
re-expression in prostate cancer cells inhibited the migration of cancer cells, suggesting 
that annexin A2 may act as an endogenous suppressor of prostate cancer cell 
dissemination. However, the relevance of reduced expression of annexin II in promoting 
the tumor metastasis of breast cancer through the association with HER-2/neu still awaits 
further investigations. 
Excessive cell proliferation and minimum cell death are fundamentals for the survival of 
the tumor cells. Increased cell mobility and flexible structural reorganization are required 
for tumor metastasis. The proposed interlinked molecular networks had recognized the 
association of HER-2/neu with the differentially regulated proteins in acquiring the 
desired phenotypes for its aggressiveness. Further characterization of these proteins may 
provide insight into the fundamental biology and pathogenic effects of HER-2/neu 
overexpression in human breast cancer.  
 
 6. Conclusions 
Further characterization of these proteins is needed to test the hypotheses derived from 
our proteomics results.  This could be performed using the breast cancer cell lines. The 
breast cancer cell line overexpressing the HER-2/neu receptor could be established. The 
expression of the identified proteins from the proteomics results could then be checked in 
this HER-2/neu overexpressing breast cancer cell line. On the other hand, the expression 
of the HER-2/neu could be silenced and the expression of these proteins could then again 
be checked. With these experiments being performed, the association of the HER-2/neu 
networks and these proteins could be firmly established.   
To further demonstrate the association of the proteins and HER-2/neu in breast tumor 
progression, the expression of the specific proteins could be targeted. The expression of 
the specific protein of interest such as Hsp27 in HER-2/neu overexpressing cell line could 
be silenced. The effect after the knock-out of the specific proteins on the HER-2/neu 
overexpressing breast cancer cell line could be studied. The tumor characteristics of a cell 
such as growth rate and the morphological changes could be observed to confirm the 
involvement of the proteins in the HER-2/neu mediated breast cancer. 
Exploitation of proteomics studies firmly established the possible molecular events of the 
signaling networks and the biochemical endpoints associated with HER-2/neu-mediated 
breast cancers. A complete picture of the underlying mechanisms of HER-2/neu- 
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 10. Appendix A 
 
3.1.1.1. Bio-Rad 
30% acrylamide/bis solution 29:1 (3.3% C)    
Ammonium persulfate (APS) 
N’, N’, N’, N’-Tetramethylethylenediamide (TEMED)  
Sequential Extraction Kit  
 
3.1.1.2. GE Healthcare  
2-D Quant Kit     
Dry strip cover fluid (mineral oil) 
Hybond-P PVDF membrane    
Immobilized pH gradient (IPG) dry-strips (7cm, pH 3-10NL, pH 4-7 and pH 3-5.6) 
IPG buffers (pH 3-10, pH 4-7, pH 3-5.6, pH 6-9) 
IPG dry-strips (18cm, pH 3-10 non-linear (NL), pH 4-7 and pH 6-9) 
 
3.1.1.3. Merck 
Acetic acid, glacial  
Acetone  
Acetonitrile 
Ethanol   
Methanol 
 
3.1.1.4. Sigma-Aldrich or Fluka 
Ammonium bicarbonate  
Formaldehyde (37%)   
Hematoxylin 
Iodoacetamide (IAA)   
Potassium ferricyanide  
Silver nitrate 
Sodium carbonate   
Sodium thiosulfate   
Thiourea 
Trifluoroacetic acid (TFA)  
 3-[3-(Cholamidopropyl)dimethylammonio]-1-propane sulfonate (CHAPS) 
 
3.1.1.5. Pierce 
Coomassie PlusTM Protein Assay Reagent 
SuperSignal West Pico Chemiluminescent Substrate 
 
3.1.1.6. Promega 
Modified porcine trypsin (Sequencing grade) 
 
3.1.1.7. Roche 
Complete Mini protease inhibitor cocktail 
 
3.1.1.8. USB Coporation 
Dithiotreitor (DTT)  
Glycine  
Soduim dodecyl sulfate (SDS)  
Sodium chloride  
Tris-base  
Urea 
 
 
